Structure-based peptide inhibitors of p53 aggregation as a new approach to cancer therapeutics

ABSTRACT

This invention relates, e.g., to an inhibitory peptide or CPP inhibitor which specifically binds to p53 having an aberrant conformation (e.g., is aggregated or misfolded) and inhibits p53 amyloidogenic aggregation or restores proper folding of the misfolded protein. Methods of using the inhibitory peptide or CPP inhibitor (e.g. to treat subjects having tumors that comprise aggregated p53) are described.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a divisional application that claims the benefitunder 35 U.S.C. § 121 of U.S. patent application Ser. No. 14/889,604(issued as U.S. Pat. No. 9,873,718), filed Nov. 6, 2015, which is theNational Stage of International Application No. PCT/US2014/037387(International Publication No. WO2014/182961), filed May 8, 2014, whichclaims priority under Section 119(e) from U.S. provisional applicationSer. No. 61/821,157, filed May 8, 2013, which is incorporated byreference herein in its entirety.

STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSOREDRESEARCH AND DEVELOPMENT

This invention was made with Government support under Grant No. NSFMCB-0958111 awarded by the National Science Foundation. The Governmenthas certain rights in the invention.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has beensubmitted electronically in ASCII format and is hereby incorporated byreference in its entirety. Said ASCII copy, created on May 8, 2014, isnamed 58086-364665_SL.txt and is 24,636 bytes in size.

BACKGROUND INFORMATION

Mutations in the tumor suppressor p53 are associated with 50% of allreported human cancers (Soussi et al., 2006). Structural instability ofp53 mutants leads to partial unfolding (Bullock and Fersht, 2001) whichin turn may cause p53 to form aggregates similar to those seen inamyloid diseases, such as Alzheimer's Disease (Xu et al, 2011; Levy etal, Eisenberg and Jucker, 2012). The process of p53 misfolding andaggregation results in protein inactivation, thereby removing the‘guardian of the genome’ from its protective function (Xu et al, 2011).

In the past decades, it has been shown that several different p53mutations, in particular those deemed to be “structural mutations,”affect p53 folding, lowering protein stability and inducing partialunfolding (Bullock and Fersht, 2001). These aberrant p53 conformationshave been demonstrated in cancer biopsies by using the mutant-specificantibody PAb240 which recognizes an epitope buried in the protein corethat gets solvent exposure only upon misfolding (Gannon et al, 1990). Inaddition, several lines of evidence have shown that fragments of p53(Ishimaru et al, Biochemistry 2003; Silva et al, 2010; Ishimaru et al,2009; Galea et al, 2005; Rigacci et al, 2008) as well as full-lengthmutant p53 (Wang et al, PNAS, 2012) undergo amyloidogenic aggregation invitro. In addition, p53 was reported to be in the misfolded aggregatedamyloid state in biopsies derived from breast cancer cases (Levy et al,2011) as well as colon carcinomas (Xu et al, 2011) and basal cellcarcinomas (Lasagna-Reeves et al, 2013).

There is a need for agents that can specifically destabilize p53aggregates or prevent them from forming, in particular agents which aredesigned in a rational structure-based approach, for use in treatingforms of cancer in which p53 is inactivated due to the fact that it isaberrantly folded and/or aggregated (is found inactive in fibrous form).Since about half of all diagnosed tumors present with p53 mutations, thepotential for applicability of such a targeted therapeutic agent isgreat.

DESCRIPTION OF THE DRAWINGS

The patent or application file contains at least one drawing executed incolor.

FIG. 1 shows the X-ray high-resolution structures of two polymorphs ofthe amyloid aggregation prone segment of p53, namely p53 residues253-258 (sequence: TIITLE (SEQ ID NO: 20)) and p53 residues 252-258(sequence: LTIITLE (SEQ ID NO: 21)). In both cases, the protofilamentsconsist of two interdigitated beta sheets, with a tight, dry interface.Three layers of the sheets are shown; water molecules are shown asyellow spheres. The top view is down the fiber axis (indicated as a reddiamond) while the bottom view is perpendicular to the axis (red arrow)

FIG. 2 shows INH-1R modeled on the p53₂₅₂₋₂₅₈ crystal structure. Threeadjacent sheets are represented. The cyan ball-and-stick inhibitor has ahigh surface complementarity to the LTIITLE (SEQ ID NO: 21) structure.The arginine (in yellow) of INH-1R collides with the opposing β-sheet,inhibiting further filament growth. The inhibitor can bind to the topand/or to the bottom (along the fiber axis) of the steric zippertemplate. The view is down the fiber axis.

FIG. 3 shows the in vitro inhibition of p53 aggregation (segmentp53₂₅₂₋₂₅₈) by INH-1R. The aggregation of p53 is monitored viaThioflavin T assay: an increase in Thioflavin T fluorescence is detectedover time due to the formation of increasing amounts of amyloid to whichthe dye can specifically bind. INH-1R is added in solution at differentconcentrations and is able to delay the aggregation onset and lower thetotal amount of aggregates present, in a concentration dependentfashion. The sequence of this segment, LTIITLE, is SEQ ID NO: 21.

FIG. 4 shows that the cell-penetrating version of INH-1R (1NH-1R CPP) isable to enter human cancer cells. INH-1R CPP was covalently linked to aFITC fluorescent label and added to different cancer cell lines orprimary cells directly obtained from ovarian cancer patients (asdepicted here). A. The peptide successfully penetrated into the cytosoland nucleus of the cells (in green) and co-localized with p53. The cellnuclei are stained with Hoechst 33342 (blue), while p53 is recognized byan anti-p53 antibody and stained in red. B. The peptide co-localizeswith protein aggregates in the same cells. Protein aggregates arestained with the commercially available OC antibody (in red). Thisindicates that INH-1R CPP binds to aggregated p53 in these ovariancancer cells.

FIG. 5 shows that INH-1R CPP causes re-localization of p53 and breaks upaggregation. In the top panels, p53 stain of primary cells from a serousovarian carcinoma patient show punctate p53 cytosolic staining. Upon 24hours of treatment with 10 μM of INH-1R CPP, all the puncta disappearedand p53 is now diffused and localized to the nucleus where it can exertits function of transcription factor and oncosuppressor as visible inthe bottom panel. Again, INH-1R CPP co-localizes with p53 (INH-1R CPP ingreen, p53 in red, nuclei in blue).

FIG. 6 shows that INH-1R CPP causes misfolded p53 to acquire a wildtype-like, functional fold. A stable cell line derived from an ovariancancer tumor is stained with the commercially available DO-1 antibodywhich recognizes any p53, irrespective of its structural state. As shownin FIG. 5, treatment with the inhibitor but not with a scrambled peptidecauses p53 to re-localize to the nucleus. In the bottom, the transitionis accompanied by a refolding step: upon treatment with the inhibitorthe antibody PAb240 does not bind to p53 in these cells, even though p53is present in abundance (see DO-1 stain above). The PAb240 commercialantibody recognizes misfolded p53, therefore loss of PAb240antigeneicity reflects a change in the p53 population from misfolded toproperly folded, functionally capable protein.

FIG. 7 shows that INH-1R CPP treated cells have a functional p53 thatcan respond to physiological regulation systems. p53 levels in OVCAR-3cell lysates treated for 24 hours with 0, 1, 5 or 10 μM INH-1R wereassessed by Western Blot and quantified using ImageJ. The total amountof p53 decreases upon 1NH-1R CPP treatment in a concentration dependentmanner. The properly folded p53 (see FIG. 6) can now be degraded as isWT p53. The hyperstability due to misfolding/aggregation is lost, andthe protein turnover is fast.

FIG. 8 shows that INH-1R CPP CPP effectively induces cell death intumors cells bearing misfolded/aggregation-prone mutant p53. A. Dosedependent reduction of cell viability was detected in cells treated with10 μM INH-1R CPP for 24 hours. Increased apoptosis (B.) and decreasedproliferation (C.) was observed with increasing INH-1R CPP dosage. B.and C. show one representative case of primary cells from ovariancancer. Similar results were observed with all sensitive primary cellsas well as cell lines.

FIG. 9 shows that INH-1R CPP effectively induces cell death in cancercells. Cells treated for 24 hours with either INH-1R or a controlpeptide were trypsinized and analyzed by FACS. Cell death is accompaniedby a typical reduction of cell size and an increase in granularity incells treated with INH-1R CPP as compared to vehicle treated cells(DMSO). Cancer cells treated with a control scrambled peptide sequencedid not show any change in cell size or granularity.

FIG. 10 shows apoptosis and necrosis in cancer cells treated with INH-1RCPP. OVCAR-3 cells were treated for 24 hours with the indicatedconcentrations of either INH-1R CPP or a scrambled inhibitor sequence.Hoechst (blue) stains all nuclei while YO-PRO-1 (green) only stainsapoptotic cells and propidium iodide (red) stains lateapoptotic/necrotic cells. The samples treated with the inhibitor containmostly dead cells, while the scrambled peptide has no effect, indicativeof sequence specific effect.

FIG. 11 shows that INH-1R CPP induces up-regulation of p53 target genesp21 and Mdm2. Specificity and efficacy of INH-1R CPP was confirmed byup-regulation of p53 target genes only in tumor cells containing p53misfolding/aggregating mutations.

FIG. 12 shows that INH-1R CPP limits tumor proliferation in vivo. A.Images of the xenografts from mice (n=3 for each group, one mouse had 2xenografts) treated with INH-1R CPP, a scrambled peptide control, orvehicle for 14 days. B. Tumors of mice treated with INH-1R CPP were sixtimes smaller compared to controls as evaluated by weight. C. Tumorvolume was estimated daily. D. Residual tumors from INH-1R CPP treatedanimals showed up-regulation of the p53 target genes MDM2 and p21.

FIG. 13 shows serum concentration of INH-1R CPP as measured by MRM(Multiple Reaction Monitoring) mass spectrometry. Nude mice wereinjected in the flank with OVCAR-3 cells and the resulting xenograftswere allowed to grow for two weeks. The mice were then treated for threedays via IP with 15 mg/kg of INH-1R CPP peptide or scrambled controlpeptide. They were divided in groups of two and sacrificed at 1, 2, 4,8, 12 and 24 hours post final peptide injection. Two naïve mice weresacrificed before treatment to obtain a reference value. Peak serumconcentration of INH-1R CPP (as well as control peptide) was detected at1 hour post injection. Average of two mice are shown.

DESCRIPTION

This application relates, e.g., to the design, synthesis and functionalcharacterization of peptides which bind specifically (preferentially) top53 protein molecules having an aberrant (e.g. pathological)conformation and which restore the conformation of the p53 moleculeshaving the aberrant conformation. The aberrant conformation can be, forexample, misfolding of the molecule resulting from a mutation in themolecule or other factors, or the formation of amyloid aggregates ofwild type or mutant p53 molecules. As a result of the restoration of theconformation, biological or biochemical activities which were lost orinhibited as a result of the aberrant conformation are reactivated orrestored. For example, the inhibitory peptides can inhibit (block)further aggregation of p53 amyloid aggregates and/or restore p53functions such as, e.g., induction or initiation of apoptosis,inhibition of cell proliferation, and/or inducing shrinkage of a tumor.In some embodiments, the peptides are fused to cell penetrating peptides(CPP) which enhance their delivery into cells.

The present inventors recently showed that it is possible to efficientlyarrest the aggregation of the Alzheimer's Disease related protein Tauand the semen-derived enhancer of HIV virus infection (SEVI) utilizingshort amino-acid inhibitors designed to specifically “cap” the growingaggregates (Sievers et al., 2011). Accordingly, there is a newtherapeutic window which targets a completely unexplored aspect of p53biology that seems to have profound effects on cancer progression, i.e.p53 misfolding resulting in aggregation. The inventors hypothesized thatmutations, overexpression or other cellular factors can destabilize thenative p53 structure, exposing an adhesive, “steric-zipper” segment,proposed as the basic building block of amyloid aggregates (Nelson etal., Nature, 2005, Sawaya et al., Nature, 2007). As reported herein, theinventors therefore obtained high atomic resolution views of the amyloidspine of p53 aggregates, and used them as a template to developstructure based peptide inhibitors that can cap the aggregates, inhibitfurther p53 aggregation and therefore generate a pool of active p53 thatcan sensitize the cancer cells to treatment and induce or initiateapoptosis. These rational structure-based inhibitors of p53 aggregationprovide a new chemotherapy efficient toward those tumors that haveproven to be the most aggressive and resilient to standard treatment,due to p53 aggregation status (Xu et al., 2011; Levy et al. 2011).

This application relates, e.g., to such inhibitory peptides; moleculesin which an inhibitory peptide of the invention is fused to a cellpenetrating peptide (CPP), which fusion molecules are sometimes referredto herein as “CPP inhibitors”; pharmaceutical compositions comprising aninhibitory peptide or a CPP inhibitor of the invention and apharmaceutically acceptable carrier; methods of using the inhibitorypeptides or the CPP inhibitors to restore the structure and function ofp53 molecules having an aberrant conformation, e.g. (a) to block orinhibit p53 aggregation (e.g., to delay the onset of aggregation and/orto lower the amount of aggregates, in solution, in a cell, or in asubject having a cancer or tumor that comprises p53 aggregates) and/or(b) to restore the folding of a misfolded p53, thereby re-activating abiological or biochemical activity of p53 due to the aberrantconformation; methods for treating a subject having a tumor whichcomprises aggregated p53 (e.g., either wild type or mutant aggregatedp53), comprising administering to the subject or contacting the tumorwith an effective amount of a CPP inhibitor of the invention; andcomputer-related embodiments, such as a method for designing andobtaining inhibitory peptides or small molecules based on the structuralrepresentation of the crystal structures described herein.

Advantages of the inhibitory peptides and CPP inhibitors of theinvention include: (1) They are selectively active only on those cancercells containing mutant or wild type aggregated p53 or misfolded p53;(2) They show no effect on folded and active p53 (no hyper-activation orincrease of p53 concentration in normal cells); (3) They areconformation specific, rather than sequence (e.g. mutation) specific. Asingle inhibitor will work for different aggregating mutants as well asfor wild type p53; (4) They can block co-aggregation of wild-type p53 aswell as aggregation of p53 with homologues and other proteins including,for example, p63 and p′73, the other members of the p53 family ofproteins (Xu et al, 2011); (5) Cell penetration and protein stabilityare not challenging obstacles, thanks to their composition and smallsize; (6) They are unexpectedly stable: they are not proteolyzed andexhibit a sufficiently long half-life to function in vivo (e.g. in abody).

One aspect of the invention is an inhibitory peptide (e.g., an isolatedpeptide) represented by the consensus sequence [L,Y,E,W] T [R,K], I T[L,Y] E (SEQ ID NO: 1), or an active variant thereof. In one embodiment,the inhibitory peptide is represented by the consensus sequence[L,Y,E,W] T R I T [L,Y] E (SEQ ID NO: 3), or an active variant thereof.The inhibitory peptide may consist of the consensus sequence [L,Y,E,W] T[R,K], I T [L,Y] E (SEQ ID NO: 1), or it may consist of the consensussequence [L,Y,E,W] T R I T [L,Y] E (SEQ ID NO: 3). In embodiments of theinvention, the inhibitory peptide may consist of, or comprise, any ofthe inhibitory peptide sequences listed in Table 1. That is, the peptidemay be LTRITLE (SEQ ID NO: 4), YTRITLE (SEQ ID NO: 5), ETRITLE (SEQ IDNO: 6), LTRIYLE (SEQ ID NO: 7), YTRIYLE (SEQ ID NO: 8), WTRITLE (SEQ IDNO: 9), WTRIYLE (SEQ ID NO: 10), ETRIYLE (SEQ ID NO: 11), LTKITLE (SEQID NO: 12), YTKITLE (SEQ ID NO: 13), WTKITLE (SEQ ID NO: 14), ETKITLE(SEQ ID NO: 15), LTKIYLE (SEQ ID NO: 16), YTKIYLE (SEQ ID NO: 17),WTRIYLE (SEQ ID NO: 10), ETKIYLE (SEQ ID NO: 18). Inhibitory peptideshaving the preceding sequences, including the active variants, aresometimes referred to herein as “inhibitory peptides of the invention.”

Another aspect of the invention is a CPP inhibitor which comprises aninhibitory peptide of the invention (including active variants) which isfused (linked, associated with, coupled), optionally via a linkersequence, to a cell penetrating peptide (CPP). The peptide can be fusedthe CPP in any of a variety of ways (e.g. chemically coupled, or fusedvia a peptide bond or other conventional means of chemical coupling).

In one embodiment, the CPP is represented by the consensus sequence(R₁₋₁₆) P I [L,Y,E,W] T [R,K], I T [L,Y] E (SEQ ID NO: 19), or an activevariant thereof. CPP inhibitors which comprise sequences encompassed bythis consensus sequence or active variants thereof are sometimesreferred to herein as “CPP inhibitors of the invention.”

Another aspect of the invention is a pharmaceutical compositioncomprising an inhibitory peptide or CPP of the invention and apharmaceutically acceptable carrier. Such pharmaceutical compositionsare sometimes referred to herein as “pharmaceutical compositions of theinvention.”

As used herein, the singular forms “a,” “an,” and “the” include pluralreferents unless the context clearly dictates otherwise. For example, inthe preceding case, the pharmaceutical composition may comprise one ormore inhibitory peptide molecules or CPPs of the invention, which can bethe same or different.

Another aspect of the invention is a complex comprising a p53 proteinmolecule and an inhibitory peptide or CPP of the invention. They may bebound to, conjugated with, or otherwise associated with each other. Thep53 and the inhibitory peptide or CPP may be covalently ornon-covalently linked.

Another aspect of the invention is a method for restoring theconformation of a p53 protein molecule having an aberrant conformation(e.g. wherein the aberrant conformation is responsible, at least inpart, for a loss of a function of the protein), comprising

contacting the p53 molecule having the aberrant conformation with aneffective amount of an inhibitory peptide or a CPP inhibitor of theinvention,

the contacted p53 having a restored conformation,

wherein the p53 molecule having the restored conformation exhibits anactivity (e.g. a restored activity) selected from the induction ofapoptosis, inhibition of cell proliferation and/or induction ofshrinkage of a tumor.

In one embodiment of this method, the p53 protein molecule which iscontacted is in a subject having cancer, and the p53 molecule having therestored conformation inhibits proliferation of cancer cells in thesubject and/or induces shrinkage of a tumor in the subject.

Another aspect of the invention is a method for preventing and/orinhibiting cell proliferation (e.g. proliferation of cancer cells)resulting from (e.g. caused by) p53 with an aberrant conformation,comprising contacting the cell with an effective amount of an inhibitorypeptide or a CPP inhibitor of the invention or with a pharmaceuticalcomposition comprising an inhibitory peptide or a CPP inhibitor of theinvention.

Another aspect of the invention is a method for treating a subjecthaving a cancer associated with (e.g. mediated by) p53 having anaberrant conformation, comprising administering to the subject aneffective amount of a pharmaceutical composition of the invention,thereby inhibiting proliferation of cancer cells in the subject and/orshrinking a tumor in the subject.

Another aspect of the invention is a method for treating a subject thathas a mutant gene encoding p53 and therefore a susceptibility to developcancers (e.g., Li-Fraumeni syndrome), comprising administering to thesubject a dose (e.g. a plurality of doses, such as by a plurality ofinjections) comprising in total an effective amount of a pharmaceuticalcomposition of the invention, thereby reducing or preventing thedevelopment of tumors in the subject.

Another aspect of the invention is a computer-implemented method foridentifying an inhibitory peptide that inhibits aggregation of p53,comprising the steps of:

identifying a template peptide sequence comprising a zipper-formingsequence of the p53 segments TIITLE (SEQ ID NO: 20) or LTIITLE (SEQ IDNO: 21) or a mirror of the zipper forming sequence from the targetpolypeptide, wherein the zipper-forming sequence aggregates into asteric zipper;

designing on a computer at least one complementary peptide sequence thatforms favorable steric and energetic intermolecular interactions withthe template peptide sequence, wherein the interactions occur at one orboth of the upper or lower ends of the steric zipper; and

identifying a candidate inhibitory peptidic compound selected from thegroup consisting of the complementary sequence, a mirror of thecomplementary sequence, a peptide mimetic of the complementary sequenceand a peptide mimetic of the mirror of the complementary sequence.

Another aspect of the invention is a kit comprising an inhibitorypeptide or CPP inhibitor of the invention, optionally packaged in acontainer.

Another aspect of the invention is a method for making an inhibitorypeptide of the invention, comprising synthesizing it chemically orproducing it recombinantly.

As described in the Examples herein, based on the determination of theatomic structure of a fiber forming segment of p53, the inventors havedesigned a series of peptide inhibitors which diminish p53 aggregation.The inventors designed peptidic inhibitors to specifically “cap” thegrowing aggregates of p53.

Using the ZipperDB algorithm (Goldschmidt et al. 2010), the inventorsidentified crystallizable amyloid-forming segments. The inventorschemically synthesized the p53₂₅₂₋₂₅₈ and p53₂₅₃₋₂₅₈ segments,crystallized them and determined their three-dimensional structures bymicro-crystallography (FIG. 1). The structures displayed a typicalsteric zipper architecture, with parallel in-register β-strands andβ-sheets interdigitating via hydrophobic side chains in a “face-to-back”(for p53₂₅₂₋₂₅₈) and “face-to-face” (for p53₂₅₃₋₂₅₈) orientation (Sawayaet al, Nature, 2007).

The inventors applied their Rosetta-based method (Sievers et al, Nature,2011) to design inhibitors that disrupt p53 aggregation, using thep53₂₅₂₋₂₅₈ structure as a template. In other embodiments of theinvention, the p53₂₅₃₋₂₅₈ structure is used as a template to designinhibitors.

Table 1 shows a list of 16 representative inhibitor sequences obtainedby this method.

TABLE 1 List of designed inhibitors of amyloidogenic p53aggregation including peptide sequences. Name Inhibitor sequenceCPP inhibitor INH-1R LTRITLE RRRRRRRRRRPILTRITLE INH-2R YTRITLERRRRRRRRRRPIYTRITLE INH-3R ETRITLE RRRRRRRRRRPIETRITLE INH-4R LTRIYLERRRRRRRRRRPILTRIYLE INH-5R YTRIYLE RRRRRRRRRRPIYTRIYLE INH-6R WTRITLERRRRRRRRRRPIWTRITLE INH-7R WTRIYLE RRRRRRRRRRPIWTRIYLE INH-8R ETRIYLERRRRRRRRRRPIETRIYLE INH-1K LTKITLE RRRRRRRRRRPILTKITLE INH-2K YTKITLERRRRRRRRRRPIYTKITLE INH-3K WTKITLE RRRRRRRRRRPIWTKITLE INH-4K ETKITLERRRRRRRRRRPIETKITLE INH-5K LTKIYLE RRRRRRRRRRPILTKIYLE INH-6K YTKIYLERRRRRRRRRRPIYTKIYLE INH-7R WTRIYLE RRRRRRRRRRPIWTRIYLE INH-8K ETKIYLERRRRRRRRRRPIETKIYLE INH-1R is the first sequence designed. INH-1R andall the other variants were synthesized fused to a poly-Arginine tag ascell penetrating peptide (CPP) and a short linker (sequence: RPI)derived from the endogenous p53 protein sequence. The inhibitingdesigned sequences are indicated with bold type, while the poly-Argininetag and linker are in normal type.The inhibitor sequences in Table 1 are, reading from top to bottom ofthe second column of the table, SEQ ID NO: 4 to SEQ ID NO: 17, 10 and18. The CPP inhibitor sequences are, reading from top to bottom of thethird column of the table, SEQ ID NO: 22 to SEQ ID NO: 35, 28 and 36.

Peptide inhibitors of the invention bind specifically (selectively,preferentially) to p53 having an aberrant conformation (e.g. aggregatedas amyloid fibrils or fibers, or partially or completely unfolded ormisfolded), in comparison to binding to other protein targets(unintended targets), such as non-aggregated or folded p53 moleculeswhich exhibit one or more of the p53-mediated functions describedherein. In fact, no binding can be detected between the peptideinhibitors of the invention and non-aggregated or folded p53 molecules.

Other suitable peptide variants include, e.g.,Leu-His-Arg-Ile-Tyr-Leu-Glu (SEQ ID NO: 37) andLeu-Tyr-Ile-Arg-Ile-Leu-Arg (SEQ ID NO: 38).

On the basis of this structural analysis, one consensus sequence, takinginto account the 16 sequences shown in Table 1, is [L,Y,E,W] T [R,K], IT [L,Y] E (SEQ ID NO: 1). In another embodiment, the consensus sequenceis [L,Y,E,W] T R I T [L,Y] E (SEQ ID NO: 3). Residues #1, 6 and, to alesser extent, #3 have the least contact with the template structure andare thus the most variable of the 7 residues.

Active variants of the sequences described above are also included.These are variants which retain the properties of the inhibitorypeptides described herein (e.g., the ability to bind specifically toaggregated p53 in a conformation-dependent, sequence-independent manner;to inhibit fibrillation of p53 to p53 or other proteins; to inhibitproliferation of cells, including cancer cells, e.g. in solution or incells in culture or in a subject; the ability to induce or initiateapoptosis; or the ability to shrink a tumor). Fibrillation, as usedherein, refers to the formation of fiber or fibrils, such as amyloidfibrils.

Suitable active variants include peptidomimetic compounds (any compoundcontaining non-peptidic structural elements that is capable of mimickingthe biochemical and/or biological action(s) of a natural mimickedpeptide, including, for example, those designed to mimic the structureand/or binding activity (such as, for example, hydrogen bonds andhydrophobic packing interactions) of the peptides according to themethods disclosed herein). Inhibitory peptides or CPP inhibitors of theinvention, including active variants thereof, are sometimes referred toherein as “peptidic compounds” or “compounds.”

In one embodiment, active variants of the inhibitory peptides areshortened by 1-3 (e.g., 1, 2 or 3) amino acids at either the N-terminus,the C-terminus, or both of the starting inhibitory peptide. In anotherembodiment, the active variants are lengthened (extended) by 1, 2, 3 or4 amino acids at the C-terminal end of the starting inhibitory peptide.

A variety of other types of active variants are encompassed. In someembodiments, amino acids other than the ones noted above in theconsensus sequence are substituted. These amino acids can help protectthe peptide inhibitors against proteolysis or otherwise stabilize thepeptides, and/or contribute to desirable pharmacodynamic properties inother ways. In some embodiments, the non-natural amino acids allow aninhibitor to bind more tightly to the target because the side chainsoptimize hydrogen bonding and/or apolar interactions with it. Inaddition, non-natural amino acids offer the opportunity of introducingdetectable markers, such as strongly fluorescent markers which can beused, e.g., to measure values such as inhibition constants. Alsoincluded are peptide mimetics, such as, e.g., peptoids, beta aminoacids, N-ethylated amino acids, and small molecule mimetics.

In one embodiment, non-natural amino acids are substituted for aminoacids in the sequence. More than 100 non-natural amino acids arecommercially available. These include, for example,

Non-Natural Amino Acids which can Substitute for LEU:

Fmoc-L-cyclohexylglycine 161321-36-4 Fmoc-L-phenylglycine 102410-65-1Fmoc-4-hydroxy-D- 178119-93-2 phenylglycine Fmoc-L-α-t-butylglycine132684-60-7 Fmoc-cyclopentyl-Gly-OH 220497-61-0 Fmoc-L-2-indanylglycine205526-39-2Non-Natural Amino Acids which can Substitute for THR:

Fmoc-Thr(tBu)-OH 71989-35-0 Fmoc-(RS)-2-amino-3- 105504-72-1hydroxy-3-methylbutanoic acidNon-Natural Amino Acids which can Substitute for ILE:

Fmoc-allo-Ile-OH 251316-98-0 Boc-N-Me-allo-Ile-OH 136092-80-3Fmoc-Homoleu-OH 180414-94-2Non-Natural Amino Acids which can Substitute for GLU:

Fmoc-γ-carboxy-L-glutamic 111662-64-7 acid Fmoc-L-α-aminosuberic acid218457-76-2Non-Natural Amino Acids which can Substitute for ARG:

Fmoc-Nω-nitro-L-arginine 58111-94-7 Fmoc-L-citrulline 133174-15-9Non-Natural Amino Acids which can Substitute for TYR:

Fmoc-3-amino-L-tyrosine 726181-70-0 Fmoc-3-nitro-L-tyrosine 136590-09-5Fmoc-3-methoxy-L-tyrosine Fmoc-3-iodo-L-tyrosine 134486-00-3Fmoc-3-chloro-L-tyrosine 478183-58-3 Fmoc-3,5-dibrimo-L-tyrosine201484-26-6Non-Natural Amino Acids which can Substitute for LYS:

Fmoc-Lys(retro-Abz-Boc)-OH 159322-59-5 Fmoc-Lys(Mca)-OH 386213-32-7Fmoc-(Nδ-4-methyltrityl)-L- 343770-23-0 ornithineN-α-Fmoc-N-ε-(d-Biotin)-L- 146987-10-2 lysine

In another embodiment, one or more (e.g. 1, 2, 3, 4, 5, 6, or 7) of theL-amino acids are substituted with a D amino acid.

In another embodiment, one or more (e.g. 1, 2, 3, 4, 5, 6, or 7)N-methylated residues are included in the peptide. Some representativesuch peptides include, e.g.,

(SEQ ID NO: 39) Leu-Thr-(Nme)Arg-Ile-Tyr-Leu-Glu (SEQ ID NO: 40)Leu-Thr-Arg-Ile-(Nme)Tyr-Leu-Glu (SEQ ID NO: 41)Leu-Thr-Arg-Ile-Tyr-(Nme)Leu-Glu (SEQ ID NO: 42)Leu-Thr-Arg-(Nme)Ile-Tyr-Leu-Glu

An inhibitory peptide of the invention can comprise, e.g., L-aminoacids, D-amino acids, non-natural amino acids, or combinations thereof.

In one embodiment, the inhibitor is a small molecule which has beendesigned by the methods described by Jiang et al. eLife 2013 (which isincorporated herein by reference, particularly with regard to thismethod), using the atomic structure of one of the fiber forming segmentsof p53 described herein as the basis for designing the inhibitor.Suitable small molecules that can be identified by this method of Jianget al. will be evident to a skilled worker.

In one embodiment of the invention, a peptide of the invention ismodified so that 1, 2 or 3 of its amino acids are substituted with anamino acid having a non-naturally occurring side chain, such as thenon-natural amino acids discussed above, or with an amino acid having aside chain modified by cross-linking (e.g., through the epsilon aminogroup of a Lys residue) of a small molecule which has been designed byJiang et al. eLife 2013. Some representative fiber-binding molecules areshown below. These active variants not only cap growing aggregates ofp53 but also, via the modified side chains, bind to (clamp against) thesides of the steric zipper, thereby enhancing the inhibitory activity ofthe peptide.

Fiber-binding compounds designed by Jiang et al. eLife 2013 include:

To enhance the cell permeability of inhibitory peptides of theinvention, they can be fused to any of a variety of cell penetratingpeptides (CPP's). CPPs typically have an amino acid composition thateither contains a high relative abundance of positively charged aminoacids such as lysine or arginine or has sequences that contain analternating pattern of polar/charged amino acids and non-polar,hydrophobic amino acids. These two types of structures are referred toas polycationic or amphipathic, respectively. A third class of CPP's arethe hydrophobic peptides, containing only apolar residues, with low netcharge or have hydrophobic amino acid groups that are crucial forcellular uptake. Some typical CPP's that can be fused to an inhibitorypeptide of the invention are provided in Table 2.

TABLE 2 Name Sequence Reference - original or review polyARGnR where 4 < n < 17 (e.g., n =5, 6,7, 8, 9, 10, 11, 12, 13, 14, 15 or 16) (SEQ ID NO: 43)Wender, P. A., Mitchell, D. J., Pattabiraman, K., Pelkey, E. T., Steinman, L., and Rothbard, J. B.(2000). The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake:peptoid molecular transporters. Proc. Natl. Acad. Sci. U.S.A. 97, 13003-8.polyLYS nK where 4 < K < 17 (e.g., K =5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16) (SEQ ID NO: 44) D-polyARGnR where 4 < n < 17 (e.g., n =5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16) D-polyLYS nK where 4 < K <17 (e.g., K = 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16) SynB1RGGRLSYSRRRFSTSTGR (SEQ ID NO: 45) SynB3 RRLSYSRRRF (SEQ ID NO: 46)Penetratin RQIKIWFQNRRMKWKK (SEQ ID NO: 47)Derossi, D., Joliot, A. H., Chassaing, G., and Prochiantz, A. (1994). The third helix of theAntennapedia homeodomain translocates through biological mem-branes. J. Biol. Chem. 269,10444-50. PenArg RQIRIWFQNRRMRWRR (SEQ ID NO: 48) PenLysKQIKIWFQNKKMKWKK (SEQ ID NO: 49) TatP59W GRKKRRQRRRPWQ (SEQ ID NO: 50)Tat (48-60) GRKKRRQRRRPPQ (SEQ ID NO: 51)Vives, E., Brodin, P., and Lebleu, B. (1997). A truncated HIV-1 Tat protein basic domain rapidlytranslocates through the plasma membrane and accumulates in the cell nucleus. J. Biol. Chem. 272,16010-7. R9-Tat GRRRRRRRRRPPQ (SEQ ID NO: 52)Futaki, S. (2002) Arginine-rich peptides: potential for intracellular delivery of macromolecules andthe mystery of the translocation mechanisms. Int. J. Pharm. 245, 1-7.Tat YGRKKRRQRRR (SEQ ID NO: 53)Vives, E., Brodin, P., and Lebleu, B. (1997). A truncated HIV-1 Tat protein basic domain rapidlytranslocates through the plasma membrane and accumulates in the cell nucleus. J. Biol. Chem. 272,16010-7. D-Tat GRKKRRQRRRPPQ (SEQ ID NO: 51)Futaki, S. (2002) Arginine-rich peptides: potential for intracellular delivery of macromolecules andthe mystery of the translocation mechanisms. Int. J. Pharm. 245, 1-7.BMVGag(7-25) KMTRAQRRAAARRNRWTAR (SEQ ID NO: 54)Futaki, S. (2002) Arginine-rich peptides: potential for intracellular delivery of macromolecules andthe mystery of the translocation mechanisms. Int. J. Pharm. 245, 1-7.FHVCoat(35-49) RRRRNRTRRNRRRVR (SEQ ID NO: 55)Futaki, S. (2002) Arginine-rich peptides: potential for intracellular delivery of macromolecules andthe mystery of the translocation mechanisms. Int. J. Pharm. 245, 1-7.HTLV-II Rex(4-16) TRRQRTRRARRNR (SEQ ID NO: 56)Futaki, S. (2002) Arginine-rich peptides: potential for intracellular delivery of macromolecules andthe mystery of the translocation mechanisms. Int. J. Pharm. 245, 1-7.P22 N-(14-30) NAKTRRHERRRKLAIER (SEQ ID NO: 57) pVECLLIILRRRIRKQAHAHSK (SEQ ID NO: 58)Elmquist, A., Lindgren, M., Bartfai, T., and Langel, U. (2001). VE-cadherin-derived cell-penetrating peptide, pVEC, with carrier functions. Exp. Cell Res. 269, 237-44.Transportan GWTLNSAGYLLGKINLKALAALAKKIL (SEQ ID NO: 59)Pooga, M., Hallbrink, M., Zorko, M., and Langel, Ü. (1998). Cell penetration by transportan.FASEB J. 12, 67-77. TP10 AGYLLGKINLKALAALAKKIL (SEQ ID NO: 60)Soomets, U., Lindgren, M., Gallet, X., Hallbrink, M., Elmquist, A., Balaspiri, L., Zorko, M., Pooga,M., Brasseur, R., and Langel, Ü. (2000). Dele-tion analogues of transportan. Biochim. Biophys.Acta 1467, 165-76. PTD-4 PIRRRKKLRRLK (SEQ ID NO: 61) PTD-5RRQRRTSKLMKR (SEQ ID NO: 62) Pep-1ac-KETWWETWWTEWSQPKKKRKV-cya (SEQ ID NO: 63) Pep-2ac-KETWFETWFTEWSQPKKKRKV-cya (SEQ ID NO: 64)Morris, MC, Chaloin, L, Choob, M, Archdeacon, J, Heitz, F and Divita, G (2004). Combination of anew generation of PNAs with a peptide-based carrier enables efficient targeting of cell cycleprogression. Gene Ther 11: 757-764. Pep-3ac-KWFETWFTEWPKKRK-cya (SEQ ID NO: 65)Morris, MC, Gros, E, Aldrian-Herrada, G, Choob, M, Archdeacon, J, Heitz, F et al. (2007). A non-covalent peptide-based carrier for in vivo delivery of DNA mimics. Nucleic Acids Res 35: e49.E N(1-22) MDAQTRRRERRAEKQAQWKAAN (SEQ ID NO: 66) B 21 N-(12-29)TAKTRYKARRAELIAERR (SEQ ID NO: 67) U2AF(142-153)SQMTRQARRLYV (SEQ ID NO: 68) PRP6(129-144)TRRNKRNRIQEQLNRK (SEQ ID NO: 69) MAP KLALKLALKLALALKLA (SEQ ID NO: 70)SBP MGLGLHLLVLAAALQGAWSQPKKKRKV (SEQ ID NO: 71) FBPGALFLGWLGAAGSTMGAWSQPKKKRKV (SEQ ID NO: 72) MPGac-GALFLGFLGAAGSTMGAWSQPKKKRKV-cya (SEQ ID NO: 73)Morris, MC, Vidal, P, Chaloin, L, Heitz, F and Divita, G (1997). A new peptide vector for efficientdelivery of oligonucleotides into mammalian cells. Nucleic Acids Res 25: 2730-2736.MPG(ΔNLS) ac- GALFLGFLGAAGSTMGAWSQPKSKRKV-cya (SEQ ID NO: 74) REV(34-50)TRQARRNRRRRWRERQR (SEQ ID NO: 75)Futaki, S. (2002) Arginine-rich peptides: potential for intracellular delivery of macromolecules andthe mystery of the translocation mechanisms. Int. J. Pharm. 245,1-7.ACPPs from Jiang et al., PNAS 2004 - lower case indicates D-aa. The symbol “__”in someof these sequences indicates a position at which any of a variety of art-recognized proteasecleavage sites can be inserted: EEEEEDDDDK_AXRRRRRRRRRXC (SEQ ID NO: 76)EEEEEDDDDK_ARRRRRRRRRXC (SEQ ID NO: 77)EDDDDK_AXRRRRRRRRRXC (SEQ ID NO: 78)EEDDDDK_ARXRRXRRXRRXRRXC (SEQ ID NO: 79)DDDDDDK_ARRRRRRRRRXC (SEQ ID NO: 80) EEDDDDK_AXrrrrrrrrrXC:eeeeeeXPLG_LAGrrrrn-rrrXc eeeeeeXPLG_LAGrrn-rrrrrXcUeeeeeeeeXPLG_LAGrrrrrrrrrXk eeeeeeXPLG_LAGrrn-rrrrrXcUeeeeeeXPLG_LAGrrrrrrrrrXc UeeeeeeeeXPLG_LAGrrrrrrrrrXk[11-kDa PEG]XeeeeeeeeeXPLG_LAGrrrrrrrrrXk[11-kDa PEG]XeeeeeeeeeXLALGPGrrrrrrrrrXk F1-XrrrrrrrrrXPLG_LAGeeeeeeeeF1-XrrrrrrrrrXSGRS_Aeeeeeeee eeeeeeXSGRS_AXrrrrrrrrrXcF1-rrrrrrrrrc-_-ceeeeee

In another embodiment, the CPP is polyD(₁₋₁₆).

In general, it is advisable that the length of the CPP is rather short,e.g. less than about 30 amino acids, in order to improve stability andpharmacodynamic properties once the molecule enters a cell.

In some embodiments, the CPP is directly attached (fused) to a peptideof the invention. In other embodiments, it is desirable to separate thehighly charged CPP from the inhibitor peptide with a linker, to allowthe inhibitor to retain its activity. Any of a variety of linkers can beused. The size of the linker can range, e.g., from 1-7 or even moreamino acids (e.g., 1, 2, 3, 4, 5, 6 or 7 amino acids). In someembodiments, the linker has sequences from the endogenous p53 sequence.For example, the linker can be GGMNRRPI (SEQ ID NO: 81), or a truncatedversion thereof having 1, 2, 3, 4 or 5 of the contiguous amino acidsN-terminal to RPI fused to the inhibitory peptide. The RPI linker usedin the experiments described herein is one such linker.

In some embodiments of the invention, the CPP inhibitor is furthermodified in order to target specific cancer types specifically. Forexample,

(1) One embodiment is a modification of the approach described by RogerTsien and coworkers (Olson et al, PNAS 2010) using ACPPs, activatableCPPs that can only enter a cell after a proteolytic cleavage by a cancerspecific protease. In this embodiment, an inhibitor is targeted to aspecific cancer type by utilizing a sequence that is specific for thoseproteases primarily expressed by the cancer of interest.

(2) Another embodiment is a modification of the strategy proposed byHatakeyama and colleagues (Hatakeyama et al, PNAS 2011). These authorsobtained targeted cancer cell delivery using the carbohydrate mimeticpeptide IF7 (sequence IFLLWQR (SEQ ID NO: 82)), which binds annexin 1, acancer vasculature marker. In this embodiment, a suitable tumorvasculature marker binding peptide is fused it to a CPP inhibitor of theinvention.

(3) In another embodiment, an inhibitor is conjugated to nanoparticle.Any of a variety of suitable nanoparticles will be evident to a skilledworker. These include, e.g., empty vault shells, liposomes, polymericnanoparticles, dendrimers or the like.

In one embodiment of the invention, an inhibitory peptide or CPPinhibitor of the invention is isolated or purified, using conventionaltechniques such as the methods described herein. By “isolated” is meantseparated from components with which it is normally associated, e.g.,components present after the peptide is synthesized. An isolated peptidecan be a cleavage product of a protein which contains the peptidesequence. A “purified” inhibitory peptide can be, e.g., greater than90%, 95%, 98% or 99% pure.

In embodiments of the invention, the inhibitory peptide or CPP inhibitoris detectably labeled. Labeled peptides can be used, e.g., to betterunderstand the mechanism of action and/or the cellular location of theinhibitory peptide. Suitable labels which enable detection (e.g.,provide a detectable signal, or can be detected) are conventional andwell-known to those of skill in the art. Suitable detectable labelsinclude, e.g., radioactive active agents, fluorescent labels, and thelike. Methods for attaching such labels to a protein, or assays fordetecting their presence and/or amount, are conventional and well-known.

An inhibitory peptide or CPP inhibitor of the invention can besynthesized (e.g., chemically or by recombinant expression in a suitablehost cell) by any of a variety of art-recognized methods. In order togenerate sufficient quantities of an inhibitory peptide for use in amethod of the invention, a practitioner can, for example, usingconventional techniques, generate nucleic acid (e.g., DNA) encoding thepeptide and insert it into an expression vector, in which the sequenceis under the control of an expression control sequence such as apromoter or an enhancer, which can then direct the synthesis of thepeptide. For example, one can (a) synthesize the DNA de novo, withsuitable linkers at the ends to clone it into the vector; (b) clone theentire DNA sequence into the vector; or (c) starting with overlappingoligonucleotides, join them by conventional PCR-based gene synthesismethods and insert the resulting DNA into the vector. Suitableexpression vectors (e.g., plasmid vectors, viral, including phage,vectors, artificial vectors, yeast vectors, eukaryiotic vectors, etc.)will be evident to skilled workers, as will methods for making thevectors, inserting sequences of interest, expressing the proteinsencoded by the nucleic acid, and isolating or purifying the expressedproteins.

Another aspect of the invention is a pharmaceutical compositioncomprising one or more of the inhibitory peptides or CPP inhibitors anda pharmaceutically acceptable carrier. The components of thepharmaceutical composition may be detectably labeled, e.g. with aradioactive or fluorescent label, or with a label that is suitable fordetection by positron emission spectroscopy (PET). In some embodiments,the inhibitory peptide or CPP inhibitor is present in an effectiveamount for the desired purpose.

“Pharmaceutically acceptable” means that which is useful in preparing apharmaceutical composition that is generally safe, non-toxic, andneither biologically nor otherwise undesirable and includes that whichis acceptable for veterinary as well as human pharmaceutical use. Forexample, “pharmaceutically acceptable salts” of a compound means saltsthat are pharmaceutically acceptable, as defined herein, and thatpossess the desired pharmacological activity of the parent compound.

Other aspects of the invention include: a polynucleotide encoding aninhibitory peptide of the invention, optionally linked to a CPPsequence, which is optionally separated from the inhibitory peptide by asuitable linker. In embodiments of the invention, the polynucleotide isoperably linked to a regulatory control sequence (e.g., a promoter or anenhancer) to facilitate production of the encoded protein followingintroduction (e.g. by transfection) into a suitable cell; a cellcomprising the expression vector; and a method of making an inhibitorypeptide of the invention comprising cultivating the cell and harvestingthe polypeptide thus generated.

As used throughout this application, “about” means plus or minus 5% of avalue.

Another aspect of the invention is a kit for carrying out any of themethods described herein. The kit may comprise a suitable amount of aninhibitory peptide or CPP inhibitor of the invention; reagents forgenerating the peptide or CPP inhibitor; reagents for assays to measuretheir functions or activities; or the like. Kits of the invention maycomprise instructions for performing a method. Other optional elementsof a kit of the invention include suitable buffers, media components, orthe like; a computer or computer-readable medium providing thestructural representation of one of the crystal structures describedherein; containers; or packaging materials. Reagents for performingsuitable controls may also be included. The reagents of the kit may bein containers in which the reagents are stable, e.g., in lyophilizedform or stabilized liquids. The reagents may also be in single use form,e.g., in single reaction form for administering to a subject.

One aspect of the invention is a computer-implemented method fordesigning an inhibitory peptide which inhibits aggregation of p53, usinga method as described herein. For example, the method can compriseidentifying (e.g. with a computer) a template peptide sequencecomprising a zipper-forming sequence of the p53 segments TIITLE (SEQ IDNO: 20) or LTIITLE (SEQ ID NO: 21) or a mirror of the zipper-formingsequence (wherein the zipper-forming sequence aggregates into a stericzipper); designing on a computer at least one complementary peptidesequence that forms favorable steric and energetic intermolecularinteractions with the template peptide sequence, wherein theinteractions occur at one or both of the upper or lower ends of thesteric zipper; and identifying (e.g. with a computer) a candidateinhibitory peptidic compound selected form the group consisting of thecomplementary sequence, a mirror of the complementary sequence, apeptide mimetic of the complementary sequence and a peptide mimetic ofthe mirror of the complementary sequence. Details of this type of methodare described in the patent which issued from U.S. Ser. No. 12/702,175,which is incorporated by reference herein in its entirety, particularlywith regard to the method for designing an inhibitory peptidic compoundwhich inhibits aggregation of an amyloid-forming target polypeptide ofinterest.

In embodiments of the invention, an inhibitory compound (e.g. a peptidiccompound) designed by this method is synthesized and screened for theability to bind to and/or to inhibit aggregation of p53, e.g., using oneof the methods described herein.

Characterization of candidate inhibitory peptides or CPP inhibitors ofthe invention can be carried out by any of a variety of conventionalmethods. For example, the peptides or CPP inhibitors can be assayed forthe ability to reduce or inhibit p53 aggregation or to re-activate p53.Functional p53 can then, for example, lead to apoptosis in cells. Theassays can be carried out in vitro or in vivo.

One representative in vitro assay is the thioflavin T assay shown inFIG. 3 (Naiki, H., Higuchi, K., Hosokawa, M., and Takeda, T. (1989)Fluorometric determination of amyloid fibrils in vitro using thefluorescent dye, thioflavine T. Anal. Biochem., 177, 244-249). The assaycan be performed using a target sequence peptide, such as LTIITLE (SEQID NO: 21), or it can be performed using full-length p53 (such asrecombinant p53). In both cases, the peptide (e.g. LTIITLE) (SEQ ID NO:21) or the p53 is placed in solution with thioflavin T and increasingconcentrations of inhibitor. The assay is performed in a multiwall plate(e.g. a 384 well plate). This dye is amyloid specific and is onlyfluorescent when bound to amyloid aggregates. The fluorescence ismeasured over time, e.g. with a plate reader. Inhibition is detected asa delay in the onset of aggregation and/or less total amount ofaggregates formed.

The following assays are among the conventional functional assays whichcan be performed in cells:

1. Reduction in p53 Aggregation

p53 aggregation is measured in cancer cells, as a measure of p53inactivation (Xu et al, 2011; Lasagna-Reeves et al, 2013). Screens areperformed for changes in the total amount of aggregates present with orwithout inhibitors using, e.g., one of the following conventionalmethods:

-   -   Immunostain of the cells using amyloid conformation specific        antibodies commercially available, e.g., A11 and OC    -   Stain of cells with amyloid specific dyes, such as Thioflavin T        and Congo Red    -   Dot blot on cell lysates using OC or A11 antibodies    -   Native page gels coupled to western blots on cell lysates using        p53 specific antibodies to check for the presence/absence of        high-molecular weight p53 aggregates    -   Immunostain of the cells using different commercially available        p53 antibodies that can discriminate between abnormally or        normally folded p53

2. Re-Activation of p53 Function

As mentioned, p53 function is typically inhibited by aggregation (Xu etal, 2011; Lasagna-Reeves et al, 2013). p53 inactivation andre-activation are tested in the presence of different concentrations ofinhibitors with the following conventional approaches:

-   -   Restoration of p53 transcriptional activity measured by        quantitating the transcripts of several p53 targets by RT-PCR or        RNAseq    -   Restoration of p53 transcriptional activity measured by        detecting via Western blot several p53 targets at the protein        level    -   Ability of the inhibitor to arrest cell proliferation screening        via soft agarose culture colony forming assay    -   Ability of the inhibitor to arrest cell proliferation screening        via BrdU incorporation or reduction in Ki67 stain    -   Ability of the inhibitor to induce cell death measured via MTT        or MTS assay    -   Ability of the inhibitor to induce apoptosis measured via        caspase apoptosis kit or Annexin V stain coupled to FACS

Cells are treated with the inhibitors alone or in combination withtraditional chemotherapy as well as other chemotherapeutic moleculessuch as other targeted agents against kinases or other molecules. Any ofthe preceding methods can further comprise testing candidate inhibitorypeptides for, e.g., their ability to bind to p53, to inhibit p53fibrillation, or to sensitize cancer cells to chemotherapy, in vitro orin vivo.

One aspect of the invention is a method for reducing or inhibiting p53aggregation, comprising contacting p53 amyloid protofilaments with aneffective amount of one or more of the inhibitory peptides of CPPinhibitors of the invention. Such a method can be carried out in vitro(in solution) or in vivo (e.g. cells in culture or in a subject).

Another aspect of the invention is a method for restoring theconformation of a p53 protein molecule having an aberrant conformation.An “aberrant conformation,” as used herein, refers to a conformationwhich is different from the wild type conformation, and which results ina loss of function of the molecule. For example, p53 with an aberrantconformation can lose the ability to inhibit cell proliferation (e.g. ofcancer cells), to induce or initiate apoptosis, or to shrink a tumor.Such aberrant conformation is sometimes referred to herein aspathological conformation. The aberrant conformation can take the formof amyloid aggregates or fibers (fibrils) of p53 molecules with otherp53 molecules or with other proteins. Alternatively, the aberrantconformation can take the form of misfolding (e.g., partial or completeunfolding) of the p53 protein due to mutations or other factors. Withoutwishing to be bound by any particular mechanism, it is suggested thatthe misfolding-promoting mutations destabilize the native p53 structurecausing the hydrophobic adhesive segment p53₂₅₂₋₂₅₈ to get solventexposure. The segments rapidly interact with other p53 moleculesresulting in protein aggregation and inactivation. It is suggested thatby generating an aggregation inhibitor which blocks these segments frominteracting with each other, the aggregation process is halted and/orthe inhibitor also chaperones the misfolded p53 into an activeconformation, thereby potentially restoring a pool of functional andsoluble p53, capable of driving a cell death response.

In this method for restoring the conformation of a p53 protein having anaberrant conformation, the p53 molecule having the aberrant conformationis contacted with an effective amount of an inhibitory peptide or a CPPinhibitor of the invention. The contacted p53 molecule has a restoredconformation, and exhibits a restored or reactivated biological orbiochemical activity selected from, e.g., induction or initiation ofapoptosis, inhibition of cell proliferation and/or shrinkage of a tumor.

Another aspect of the invention is a method for reactivating orrestoring a biological or biochemical activity (function) of a p53protein which results from aberrant conformation of the p53 protein. Themethod comprises contacting the p53 protein molecule having an aberrantconformation with an effective amount of an inhibitor peptide or CPPinhibitor of the invention, wherein the biological or biochemicalactivity of the p53 molecule is induction or initiation of apoptosisand/or is inhibition of cell proliferation and/or is inducing shrinkageof a tumor. As a result of contacting the p53 protein having theaberrant conformation, the lost biological or biochemical activity ofthe p53 molecule is reactivated or restored.

Another aspect of the invention is a method for inhibiting or preventinga loss of a biological or biochemical activity (function), of a p53protein which results from aberrant conformation of the p53 protein. Themethod comprises contacting the p53 protein molecule having an aberrantconformation with an effective amount of an inhibitor peptide or CPPinhibitor of the invention, wherein the biological or biochemicalactivity of the p53 molecule is induction or initiation of apoptosisand/or is inhibition of cell proliferation and/or is inducing shrinkageof a tumor. As a result of contacting the p53 protein having theaberrant conformation, the loss of activity of the p53 molecule isinhibited or prevented.

Another aspect of the invention is a method for treating a subjecthaving a disease or condition which is mediated by loss of function ofp53, such as a cancer or a tumor in which p53 has an abnormalconformation (e.g. is aggregated or misfolded). That is, the cancer isassociated with p53 having an aberrant conformation. The methodcomprises administering to the subject an effective amount of one ormore CPPs of the invention. In some embodiments, a cocktail of one ofmore of the CPP inhibitors is used. In some embodiments, the CPPinhibitor is used in conjunction with a conventional chemotherapeuticdrug or regimen, in order to enhance the response of the subject thechemotherapeutic drug or regimen. Typical such chemotherapeutic drugs orregimens include, e.g., paclitaxel, taxol, gemcitabine, cisplatin,carboplatin, rapamycin, doxorubicin, 5-fluorouracil, trastuzumab,imatinib, sorafenib, vemurafenib, dasatinib, crizotinib, gefitinib,erlotinib, carfilzomib, PRIMA1-MET, MI-773, nutlin, and 17AAG.

An “effective amount” of a compound or pharmaceutical composition of theinvention is an amount that can elicit a measurable amount of a desiredoutcome, e.g. inhibition of p53 aggregation; for a diagnostic assay, anamount that can detect a target of interest, such as a p53 aggregate; orin a method of treatment, an amount that can reduce or ameliorate, by ameasurable amount, a symptom of the disease or condition that is beingtreated.

A “subject” can be any subject (patient) having p53 with an aberrantconformation (e.g., the p53 is aggregated or misfolded), in which thecondition or disease can be treated by a method of the presentinvention. In one embodiment of the invention, the subject has a cancer,such as one of the cancers described in Soussi et al., 2006 that areassociated with mutant p53. Typical subjects include vertebrates, suchas mammals, including laboratory animals, dogs, cats, non-human primatesand humans.

The inhibitors of the invention can be formulated as pharmaceuticalcompositions in a variety of forms adapted to the chosen route ofadministration, for example, orally, nasally, intraperitoneally, orparenterally, by intravenous, intramuscular, topical or subcutaneousroutes, or by injection into tissue.

Suitable oral forms for administering the compounds include lozenges,troches, tablets, capsules, effervescent tablets, orally disintegratingtablets, floating tablets designed to increase gastric retention times,buccal patches, and sublingual tablets.

The compounds of the invention may be systemically administered, e.g.,orally, in combination with a pharmaceutically acceptable vehicle suchas an inert diluent or an assimilable edible carrier, or by inhalationor insufflation. They may be enclosed in coated or uncoated hard or softshell gelatin capsules, may be compressed into tablets, or may beincorporated directly with the food of the patient's diet. For oraltherapeutic administration, the compounds may be combined with one ormore excipients and used in the form of ingestible tablets, buccaltablets, troches, capsules, elixirs, suspensions, syrups, wafers, andthe like. For compositions suitable for administration to humans, theterm “excipient” is meant to include, but is not limited to, thoseingredients described in Remington: The Science and Practice ofPharmacy, Lippincott Williams & Wilkins, 21st ed. (2006) (hereinafterRemington's).

The compounds may be combined with a fine inert powdered carrier andinhaled by the subject or insufflated. Such compositions andpreparations should contain at least 0.1% compounds. The percentage ofthe compositions and preparations may, of course, be varied and mayconveniently be between about 2% to about 60% of the weight of a givenunit dosage form.

The tablets, troches, pills, capsules, and the like may also contain thefollowing: binders such as gum tragacanth, acacia, corn starch orgelatin; excipients such as dicalcium phosphate; a disintegrating agentsuch as corn starch, potato starch, alginic acid and the like; alubricant such as magnesium stearate; and a sweetening agent such assucrose, fructose, lactose or aspartame or a flavoring agent such aspeppermint, oil of wintergreen, or cherry flavoring may be added. Whenthe unit dosage form is a capsule, it may contain, in addition tomaterials of the above type, a liquid carrier, such as a vegetable oilor a polyethylene glycol. A syrup or elixir may contain the activecompound, sucrose or fructose as a sweetening agent, methyl andpropylparabens as preservatives, a dye and flavoring such as cherry ororange flavor.

Various other materials may be present as coatings or to otherwisemodify the physical form of the solid unit dosage form. For instance,tablets, pills, or capsules may be coated with gelatin, wax, shellac orsugar and the like. Of course, any material used in preparing any unitdosage form should be pharmaceutically acceptable and substantiallynon-toxic in the amounts employed.

In addition, the compounds may be incorporated into sustained-releasepreparations and devices. For example, the compounds may be incorporatedinto time release capsules, time release tablets, and time releasepills. In some embodiments, the composition is administered using adosage form selected from the group consisting of effervescent tablets,orally disintegrating tablets, floating tablets designed to increasegastric retention times, buccal patches, and sublingual tablets.

The compounds may also be administered intravenously orintraperitoneally by infusion or injection. Solutions of the compoundscan be prepared in water, optionally mixed with a nontoxic surfactant.Dispersions can also be prepared in glycerol, liquid polyethyleneglycols, triacetin, and mixtures thereof and in oils. Under ordinaryconditions of storage and use, these preparations can contain apreservative to prevent the growth of microorganisms.

The pharmaceutical dosage forms suitable for injection or infusion caninclude sterile aqueous solutions or dispersions or sterile powderscomprising the compounds which are adapted for the extemporaneouspreparation of sterile injectable or infusible solutions or dispersions,optionally encapsulated in liposomes. In all cases, the ultimate dosageform should be sterile, fluid and stable under the conditions ofmanufacture and storage. The liquid carrier or vehicle can be a solventor liquid dispersion medium comprising, for example, water, ethanol, apolyol (for example, glycerol, propylene glycol, liquid polyethyleneglycols, and the like), vegetable oils, nontoxic glyceryl esters, andsuitable mixtures thereof. The proper fluidity can be maintained, forexample, by the formation of liposomes, by the maintenance of therequired particle size in the case of dispersions or by the use ofsurfactants.

Sterile injectable solutions are prepared by incorporating the compoundsin the required amount in the appropriate solvent with various of theother ingredients enumerated above, as required, followed by filtersterilization. In the case of sterile powders for the preparation ofsterile injectable solutions, the preferred methods of preparation arevacuum drying and freeze drying techniques, which yield a powder of theactive ingredient plus any additional desired ingredient present in thepreviously sterile-filtered solutions.

For topical administration, the compounds may be applied in pure form.However, it will generally be desirable to administer them to the skinas compositions or formulations, in combination with a dermatologicallyacceptable carrier, which may be a solid or a liquid.

Useful solid carriers include finely divided solids such as talc, clay,microcrystalline cellulose, silica, alumina and the like. Other solidcarriers include conventional nontoxic polymeric nanoparticles ormicroparticles. Useful liquid carriers include water, alcohols orglycols or water/alcohol/glycol blends, in which the compounds can bedissolved or dispersed at effective levels, optionally with the aid ofnon-toxic surfactants. Adjuvants such as fragrances and additionalantimicrobial agents can be added to optimize the properties for a givenuse. The resultant liquid compositions can be applied from absorbentpads, used to impregnate bandages and other dressings, or sprayed ontothe affected area using pump-type or aerosol sprayers.

Useful dosages of the compounds of formula 1 can be determined bycomparing their in vitro activity, and in vivo activity in animalmodels. Methods for the extrapolation of effective dosages in mice, andother animals, to humans are known to the art.

For example, the concentration of the compounds in a liquid composition,such as a lotion, can be from about 0.1-25% by weight, or from about0.5-10% by weight. The concentration in a semi-solid or solidcomposition such as a gel or a powder can be about 0.1-5% by weight, orabout 0.5-2.5% by weight.

Effective dosages and routes of administration of agents of theinvention are conventional. The exact amount (effective dose) of theagent will vary from subject to subject, depending on, for example, thespecies, age, weight and general or clinical condition of the subject,the severity or mechanism of any disorder being treated, the particularagent or vehicle used, the method and scheduling of administration, andthe like. A therapeutically effective dose can be determinedempirically, by conventional procedures known to those of skill in theart. See, e.g, The Pharmacological Basis of Therapeutics, Goodman andGilman, eds., Macmillan Publishing Co., New York. For example, an,effective dose can be estimated initially either in cell culture assaysor in suitable animal models. The animal model may also be used todetermine the appropriate concentration ranges and routes ofadministration. Such information can then be used to determine usefuldoses and routes for administration in humans. A therapeutic dose canalso be selected by analogy to dosages for comparable therapeuticagents.

The particular mode of administration and the dosage regimen will beselected by the attending clinician, taking into account the particularsof the case (e.g., the subject, the disease, the disease state involved,and whether the treatment is prophylactic). Treatment may involve dailyor multi-daily doses of compound(s) over a period of a few days tomonths, or even years.

In general, however, a suitable dose will be in the range of from about0.001 to about 100 mg/kg, e.g., from about 0.01 to about 100 mg/kg ofbody weight per day, such as above about 0.1 mg per kilogram, or in arange of from about 1 to about 10 mg per kilogram body weight of therecipient per day. For example, a suitable dose may be about 1 mg/kg, 10mg/kg, or 50 mg/kg of body weight per day.

The compounds are conveniently administered in unit dosage form; forexample, containing 0.05 to 10000 mg, 0.5 to 10000 mg, 5 to 1000 mg, orabout 100 mg of active ingredient per unit dosage form. In someembodiments, the dosage unit contains about 1 mg, about 10 mg, about 25mg, about 50 mg, about 75 mg, about 100 mg, about 150 mg, about 200 mg,about 250 mg, about 300 mg, about 350 mg, about 400 mg, about 450 mg,about 500 mg, about 750 mg, or about 1000 mg of active ingredient.

The invention also includes computer-related embodiments, such as acomputer-readable medium, providing the structural representation of oneof the crystal structures described herein, or for storing and/orevaluating the assay results described herein.

The storage medium (computer readable medium) in which the p53structural representation is provided may be, e.g., random-access memory(RAM), read-only memory (ROM e.g. CDROM), a diskette, magnetic storagemedia, hybrids of these categories, etc. The storage medium may be localto the computer, or may be remote (e.g. a networked storage medium,including the internet). The present invention also provides methods ofproducing computer readable databases containing coordinates of 3-Dstructures of the invention; computer readable media embedded with orcontaining information regarding the 3-D structure of the invention; acomputer programmed to carry out a method of the invention (e.g. forcharacterizing the structure of a p53 segment or for designing and/orselecting peptidic inhibitors), and data carriers having a program savedthereon for carrying out a method as described herein.

Any suitable computer can be used in the present invention.

An exemplary architecture for implementing a computing device inaccordance with one or more embodiments, which may be used to implementany of the computing devices discussed herein, or any other computersystem or computing device component thereof is described below. It willbe appreciated that other devices that can be used with this computingdevice, such as a client or a server, may be similarly configured. Thecomputing device may include a bus, a processor, a memory, a read onlymemory (ROM), a storage device, an input device, an output device, and acommunication interface.

The bus may include one or more interconnects that permit communicationamong the components of the computing device. The processor may includeany type of processor, microprocessor, or processing logic that mayinterpret and execute instructions (e.g., a field programmable gatearray (FPGA)). The processor may include a single device (e.g., a singlecore) and/or a group of devices (e.g., multi-core). The memory mayinclude a random access memory (RAM) or another type of dynamic storagedevice that may store information and instructions for execution by theprocessor. The memory may also be used to store temporary variables orother intermediate information during execution of instructions by theprocessor.

The ROM may include a ROM device and/or another type of static storagedevice that may store static information and instructions for theprocessor. The storage device may include a magnetic disk and/or opticaldisk and its corresponding drive for storing information and/orinstructions. The storage device may include a single storage device ormultiple storage devices, such as multiple storage devices operating inparallel. Moreover, the storage device may reside locally on thecomputing device and/or may be remote with respect to a server andconnected thereto via network and/or another type of connection, such asa dedicated link or channel.

The input device may include any mechanism or combination of mechanismsthat permit an operator to input information to the computing device,such as a keyboard, a mouse, a touch sensitive display device, amicrophone, a pen-based pointing device, and/or a biometric inputdevice, such as a voice recognition device and/or a finger printscanning device. The output device may include any mechanism orcombination of mechanisms that outputs information to the operator,including a display, a printer, a speaker, etc.

The communication interface may include any transceiver-like mechanismthat enables the computing device to communicate with other devicesand/or systems, such as a client, a server, a license manager, a vendor,etc. For example, the communication interface may include one or moreinterfaces, such as a first interface coupled to a network and/or asecond interface coupled to a license manager. Alternatively, thecommunication interface may include other mechanisms (e.g., a wirelessinterface) for communicating via a network, such as a wireless network.In one implementation, the communication interface may include logic tosend code to a destination device, such as a target device that caninclude general purpose hardware (e.g., a personal computer formfactor), dedicated hardware (e.g., a digital signal processing (DSP)device adapted to execute a compiled version of a model or a part of amodel), etc.

The computing device may perform certain functions in response to theprocessor executing software instructions contained in acomputer-readable medium, such as memory. In alternative embodiments,hardwired circuitry may be used in place of or in combination withsoftware instructions to implement features consistent with principlesof the disclosure. Thus, implementations consistent with principles ofthe disclosure are not limited to any specific combination of hardwarecircuitry and software.

Exemplary embodiments may be embodied in many different ways as asoftware component. For example, it may be a stand-alone softwarepackage, a combination of software packages, or it may be a softwarepackage incorporated as a “tool” in a larger software product. It may bedownloadable from a network, for example, a website, as a stand-aloneproduct or as an add-in package for installation in an existing softwareapplication. It may also be available as a client-server softwareapplication, or as a web-enabled software application. It may also beembodied as a software package installed on a hardware device.

EXAMPLES Example I—Design and Characterization of Inhibitory Peptidesand CPP Inhibitors

Based on the determination of the atomic structure of a fiber formingsegment of p53, the inventors rationally designed a series of inhibitorsthat diminish aggregation in vitro. The inventors designed peptidicinhibitors to “cap” the growing aggregates of p53. Using the ZipperDBalgorithm (Goldschmidt et al. 2010), the inventors identified thecrystallizable amyloid-forming segments in the region that was alsoreported to be important for mutant p53 aggregation by Xu et al., 2011,who identified the sequence ILTIITL (SEQ ID NO: 2). The presentinventors chemically synthesized the p53₂₅₂₋₂₅₈ and p53₂₅₃₋₂₅₈ segments,crystallized them and determined their three-dimensional structures bymicro-crystallography (FIG. 1). The structures displayed a typicalsteric zipper architecture, with parallel in-register β-strands andβ-sheets interdigitating via hydrophobic side chains in a “face-to-back”(for p53₂₅₂₋₂₅₈) and “face-to-face” (for p53₂₅₃₋₂₅₈) orientation (Sawayaet al, Nature, 2007).

The atomic coordinates of the p53₂₅₃₋₂₅₈ (TITTLE) (SEQ ID NO: 20) andp53₂₅₂₋₂₅₈ (LTIITLE) (SEQ ID NO: 21) structures are shown in Tables 3and 4, respectively.

TABLE 3 REMARK Date 2012-02-17 Time 19:46:52 PST −0800 (1329536812.65 s)REMARK PHENIX refinement REMARK REMARK ****************** INPUT FILESAND LABELS ******************* REMARK Reflections: REMARK file name:t6e_all.mtz REMARK labels: [‘IMEAN, SIGIMEAN’] REMARK R-free flags:REMARK file name: t6e_all.mtz REMARK label: FreeR_flag REMARKtest_flag_value: 0 REMARK Model file name(s): REMARK/home/absoriaga/APS/T6E/1.59A/build006_001-coot-0.pdb REMARK REMARK******************** REFINEMENT SUMMARY: QUICK FACTS ********* REMARKStart: r_work = 0.1678 r_free = 0.1910 bonds = 0.009 angles = 1.861REMARK Final: r_work = 0.1637 r_free = 0.1925 bonds = 0.009 angles =1.861 REMARK*********************************************************************REMARK REMARK Rigid body refinement target: auto REMARK Informationabout total rigid body shift of selected groups: REMARK rotation (deg)translation (A) REMARK xyz total xyz total REMARK group 1: −0.342 −0.3010.287 0.54 −0.02 0.03 0.02 0.04 REMARK group 2: −0.000 0.000 0.000 0.000.01 −0.02 0.01 0.02 REMARK group 3: −0.029 −0.173 −0.204 0.27 0.01−0.01 0.05 0.05 REMARK ****************** REFINEMENT STATISTICS STEP BYSTEP ******* REMARK leading digit, like 1_, means number of macro-cycleREMARK 0 : statistics at the very beginning when nothing is done yetREMARK 1_bss: bulk solvent correction and/or (anisotropic) scalingREMARK 1_rbr: rigid body refinement REMARK-------------------------------------------------------------- REMARKR-factors, x-ray target values and norm of gradient of x-ray targetREMARK stage r-work r-free xray_target_w xray_target_t REMARK 0 : 0.17020.1913 1.200965e+00 1.236068e+00 REMARK 1_bss: 0.1678 0.19101.166180e+00 1.232305e+00 REMARK 1_ohs: 0.1678 0.1910 1.166180e+001.232305e+00 REMARK 1_rbr: 0.1678 0.1904 1.169224e+00 1.233750e+00REMARK 1_adp: 0.1659 0.1935 1.164208e+00 1.257252e+00 REMARK 2_bss:0.1657 0.1933 1.164333e+00 1.256966e+00 REMARK 2_ohs: 0.1657 0.19331.164333e+00 1.256966e+00 REMARK 2_adp: 0.1634 0.1913 1.153688e+001.227758e+00 REMARK 3_bss: 0.1634 0.1911 1.153695e+00 1.227577e+00REMARK 3_ohs: 0.1634 0.1911 1.153695e+00 1.227577e+00 REMARK 3_adp:0.1637 0.1925 1.158500e+00 1.245755e+00 REMARK 3_ohs: 0.1637 0.19251.158500e+00 1.245755e+00 REMARK-------------------------------------------------------------- REMARKstage k_sol b_sol b11 b22 b33 b12 b13 b23 REMARK 0 : 0.400 80.000 −2.3850.077 2.308 −0.000 −0.841 0.000 REMARK 1_bss: 0.444 141.213 −2.385 0.0772.308 −0.000 −0.841 −0.000 REMARK 1_ohs: 0.444 141.213 −2.385 0.0772.308 −0.000 −0.841 −0.000 REMARK 1_rbr: 0.400 80.000 −2.385 0.077 2.308−0.000 −0.841 −0.000 REMARK 1_adp: 0.400 80.000 −2.385 0.077 2.308−0.000 −0.841 −0.000 REMARK 2_bss: 0.400 80.000 −2.399 0.015 2.229−0.000 −0.834 0.000 REMARK 2_ohs: 0.400 80.000 −2.399 0.015 2.229 −0.000−0.834 0.000 REMARK 2_adp: 0.400 80.000 −2.399 0.015 2.229 −0.000 −0.8340.000 REMARK 3_bss: 0.400 80.000 −2.407 −0.032 2.194 −0.000 −0.819 0.000REMARK 3_ohs: 0.400 80.000 −2.407 −0.032 2.194 −0.000 −0.819 0.000REMARK 3_adp: 0.400 80.000 −2.407 −0.032 2.194 −0.000 −0.819 0.000REMARK 3_ohs: 0.400 80.000 −2.407 −0.032 2.194 −0.000 −0.819 0.000REMARK --------------------------------------------------------------REMARK stage <pher> fom alpha beta REMARK 0 : 15.419 0.8841 0.0567 1.306REMARK 1_bss: 15.363 0.8845 0.0567 1.295 REMARK 1_ohs: 15.363 0.88450.0567 1.295 REMARK 1_rbr: 15.338 0.8848 0.0568 1.298 REMARK 1_adp:15.919 0.8793 0.0578 1.377 REMARK 2_bss: 15.892 0.8796 0.0577 1.375REMARK 2_ohs: 15.892 0.8796 0.0577 1.375 REMARK 2_adp: 15.280 0.88560.0576 1.290 REMARK 3_bss: 15.263 0.8858 0.0575 1.289 REMARK 3_ohs:15.263 0.8858 0.0575 1.289 REMARK 3_adp: 15.698 0.8817 0.0577 1.347REMARK 3_ohs: 15.698 0.8817 0.0577 1.347 REMARK-------------------------------------------------------------- REMARKstage angl bond chir dihe plan repu geom_target REMARK 0 : 1.861 0.0090.072 10.557 0.007 4.221 3.0983e−01 REMARK 1_bss: 1.861 0.009 0.07210.557 0.007 4.221 3.0983e−01 REMARK 1_ohs: 1.861 0.009 0.072 10.5570.007 4.221 3.0983e−01 REMARK 1_rbr: 1.861 0.009 0.072 10.557 0.0074.221 3.0983e−01 REMARK 1_adp: 1.861 0.009 0.072 10.557 0.007 4.2213.0983e−01 REMARK 2_bss: 1.861 0.009 0.072 10.557 0.007 4.221 3.0983e−01REMARK 2_ohs: 1.861 0.009 0.072 10.557 0.007 4.221 3.0983e−01 REMARK2_adp: 1.861 0.009 0.072 10.557 0.007 4.221 3.0983e−01 REMARK 3_bss:1.861 0.009 0.072 10.557 0.007 4.221 3.0983e−01 REMARK 3_ohs: 1.8610.009 0.072 10.557 0.007 4.221 3.0983e−01 REMARK 3_adp: 1.861 0.0090.072 10.557 0.007 4.221 3.0983e−01 REMARK 3_ohs: 1.861 0.009 0.07210.557 0.007 4.221 3.0983e−01 REMARK-------------------------------------------------------------- REMARKMaximal deviations: REMARK stage angl bond chir dihe plan repu |grad|REMARK 0 : 9.207 0.052 0.183 22.762 0.017 1.935 7.3928e−01 REMARK 1_bss:9.207 0.052 0.183 22.762 0.017 1.935 7.3928e−01 REMARK 1_ohs: 9.2070.052 0.183 22.762 0.017 1.935 7.3928e−01 REMARK 1_rbr: 9.207 0.0520.183 22.762 0.017 1.935 7.3928e−01 REMARK 1_adp: 9.207 0.052 0.18322.762 0.017 1.935 7.3928e−01 REMARK 2_bss: 9.207 0.052 0.183 22.7620.017 1.935 7.3928e−01 REMARK 2_ohs: 9.207 0.052 0.183 22.762 0.0171.935 7.3928e−01 REMARK 2_adp: 9.207 0.052 0.183 22.762 0.017 1.9357.3928e−01 REMARK 3_bss: 9.207 0.052 0.183 22.762 0.017 1.935 7.3928e−01REMARK 3_ohs: 9.207 0.052 0.183 22.762 0.017 1.935 7.3928e−01 REMARK3_adp: 9.207 0.052 0.183 22.762 0.017 1.935 7.3928e−01 REMARK 3_ohs:9.207 0.052 0.183 22.762 0.017 1.935 7.3928e−01 REMARK------------------------------------------------------------------------ REMARK|-----overall-----|---macromolecule----|------solvent-------| REMARKstage b_max b_min b_ave b_max b_min b_ave b_max b_min b_ave REMARK 0 :18.10 2.58 6.49 15.36 2.58 6.16 18.10 11.08 14.59 REMARK 1_bss: 18.102.58 6.49 15.36 2.58 6.16 18.10 11.08 14.59 REMARK 1_ohs: 18.10 2.586.49 15.36 2.58 6.16 18.10 11.08 14.59 REMARK 1_rbr: 18.10 2.58 6.4915.36 2.58 6.16 18.10 11.08 14.59 REMARK 1_adp: 19.05 2.88 7.12 16.062.88 6.80 19.05 10.85 14.95 REMARK 2_bss: 19.05 2.88 7.12 16.06 2.886.80 19.05 10.85 14.95 REMARK 2_ohs: 19.05 2.88 7.12 16.06 2.88 6.8019.05 10.85 14.95 REMARK 2_adp: 25.77 2.48 7.00 15.92 2.48 6.46 25.7714.73 20.25 REMARK 3_bss: 25.77 2.48 7.00 15.92 2.48 6.46 25.77 14.7320.25 REMARK 3_ohs: 25.77 2.48 7.00 15.92 2.48 6.46 25.77 14.73 20.25REMARK 3_adp: 26.28 2.54 7.43 16.68 2.54 6.90 26.28 14.91 20.59 REMARK3_ohs: 26.28 2.54 7.43 16.68 2.54 6.90 26.28 14.91 20.59 REMARK------------------------------------------------------------------------ REMARK stage Deviation of refined REMARK model from start modelREMARK max min mean REMARK 0 : 0.000 0.000 0.000 REMARK 1_bss: 0.0000.000 0.000 REMARK 1_ohs: 0.000 0.000 0.000 REMARK 1_rbr: 0.000 0.0000.000 REMARK 1_adp: 0.000 0.000 0.000 REMARK 2_bss: 0.000 0.000 0.000REMARK 2_ohs: 0.000 0.000 0.000 REMARK 2_adp: 0.000 0.000 0.000 REMARK3_bss: 0.000 0.000 0.000 REMARK 3_ohs: 0.000 0.000 0.000 REMARK 3_adp:0.000 0.000 0.000 REMARK 3_ohs: 0.000 0.000 0.000 REMARK------------------------------------------------------------------------ REMARK MODEL CONTENT. REMARK ELEMENT ATOM RECORD COUNT OCCUPANCYSUM REMARK C 31 31.00 REMARK Zn 1 1.00 REMARK O 13 13.00 REMARK N 6 6.00REMARK TOTAL 51 51.00 REMARK------------------------------------------------------------------ -----REMARK r_free_flags.md5.hexdigest 250b0898748f0b3eeb957968c7c1d593REMARK REMARK IF THIS FILE IS FOR PDB DEPOSITION: REMOVE ALL FROM THISLINE UP. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM: PHENIX(phenix.refine: 1.7.3_928) REMARK 3 AUTHORS: Adams, Afonine, Chen,Davis, Echols, Gildea, Gopal, REMARK 3 : Grosse-Kunstleve, Headd, Hung,Immormino, Ioerger, McCoy, REMARK 3 : McKee, Moriarty, Pai, Read,Richardson, Richardson, Romo, REMARK 3 : Sacchettini, Sauter, Smith,Storoni, Terwilliger, Zwart REMARK 3 REMARK 3 REFINEMENT TARGET: MLREMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGEHIGH (ANGSTROMS): 1.576 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS):21.494 REMARK 3 MIN(FOBS/SIGMA_FOBS): 1.43 REMARK 3 COMPLETENESS FORRANGE (%): 93.38 REMARK 3 NUMBER OF REFLECTIONS: 635 REMARK 3 NUMBER OFREFLECTIONS (NON-ANOMALOUS): 635 REMARK 3 REMARK 3 FIT TO DATA USED INREFINEMENT. REMARK 3 R VALUE (WORKING + TEST SET): 0.1666 REMARK 3 RVALUE (WORKING SET): 0.1637 REMARK 3 FREE R VALUE: 0.1925 REMARK 3 FREER VALUE TEST SET SIZE (%): 10.24 REMARK 3 FREE R VALUE TEST SET COUNT:65 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (IN BINS). REMARK 3BIN RESOLUTION RANGE COMPL. NWORK NFREE RWORK RFREE REMARK 3 121.4963-1.5756 0.93 570 65 0.1637 0.1925 REMARK 3 REMARK 3 BULK SOLVENTMODELLING. REMARK 3 METHOD USED: FLAT BULK SOLVENT MODEL REMARK 3SOLVENT RADIUS: 1.00 REMARK 3 SHRINKAGE RADIUS: 0.73 REMARK 3 GRID STEPFACTOR: 4.00 REMARK 3 K_SOL: 0.400 REMARK 3 B_SOL: 80.000 REMARK 3REMARK 3 ERROR ESTIMATES. REMARK 3 COORDINATE ERROR (MAXIMUM-LIKELIHOODBASED): 0.10 REMARK 3 PHASE ERROR (DEGREES, MAXIMUM-LIKELIHOOD BASED):15.70 REMARK 3 REMARK 3 OVERALL SCALE FACTORS. REMARK 3 SCALE =SUM(|F_OBS|*|F_MODEL|)/SUM(|F_MODEL|**2): 0.0589 REMARK 3 ANISOTROPICSCALE MATRIX ELEMENTS (IN CARTESIAN BASIS). REMARK 3 B11: −2.4068 REMARK3 B22: −0.0323 REMARK 3 B33: 2.1936 REMARK 3 B12: −0.0000 REMARK 3 B13:−0.8190 REMARK 3 B23: 0.0000 REMARK 3 REMARK 3 R FACTOR FORMULA. REMARK3 R = SUM(||F_OBS|−SCALE*|F_MODEL||)/SUM(|F_OBS|) REMARK 3 REMARK 3TOTAL MODEL STRUCTURE FACTOR (F_MODEL). REMARK 3 F_MODEL = FB_CART *(F_CALC_ATOMS + F_BULK) REMARK 3 F_BULK = K_SOL * EXP(−B_SOL * S**2/4) *F_MASK REMARK 3 F_CALC_ATOMS = ATOMIC MODEL STRUCTURE FACTORS REMARK 3FB_CART = EXP(−H(t) * A(−1) * B * A(−1t) * H) REMARK 3 A =orthogonalization matrix, H = MILLER INDEX REMARK 3 (t) = TRANSPOSE,(−1) = INVERSE REMARK 3 REMARK 3 STRUCTURE FACTORS CALCULATIONALGORITHM: FFT REMARK 3 REMARK 3 DEVIATIONS FROM IDEAL VALUES. REMARK 3RMSD MAX COUNT REMARK 3 BOND: 0.009 0.052 47 REMARK 3 ANGLE: 1.861 9.20764 REMARK 3 CHIRALITY: 0.072 0.183 11 REMARK 3 PLANARITY: 0.007 0.017 7REMARK 3 DIHEDRAL: 10.557 22.762 17 REMARK 3 MIN NONBONDED DISTANCE:1.935 REMARK 3 REMARK 3 MOLPROBITY STATISTICS. REMARK 3 ALL-ATOMCLASHSCORE: 9.62 REMARK 3 RAMACHANDRAN PLOT: REMARK 3 OUTLIERS: 0.00%REMARK 3 ALLOWED: 0.00% REMARK 3 FAVORED: 100.00% REMARK 3 ROTAMEROUTLIERS: 0.00% REMARK 3 CBETA DEVIATIONS: 0 REMARK 3 REMARK 3 ATOMICDISPLACEMENT PARAMETERS. REMARK 3 WILSON B: 3.10 REMARK 3RMS(B_ISO_OR_EQUIVALENT_BONDED): 2.15 REMARK 3 ATOMS NUMBER OF ATOMSREMARK 3 ISO. ANISO. REMARK 3 ALL: 51 51 REMARK 3 ALL (NO H): 51 51REMARK 3 SOLVENT: 2 2 REMARK 3 NON-SOLVENT: 49 49 REMARK 3 HYDROGENS: 00 REMARK 3 REMARK 3 TLS DETAILS. REMARK 3 NUMBER OF TLS GROUPS: 1 REMARK3 ORIGIN: CENTER OF MASS REMARK 3 TLS GROUP: 1 REMARK 3 SELECTION: allREMARK 3 ORIGIN FOR THE GROUP (A): 10.5250 −0.1582 3.9867 REMARK 3 TTENSOR REMARK 3 T11: 0.0284 T22: 0.0494 REMARK 3 T33: 0.0290 T12: 0.0055REMARK 3 T13: 0.0058 T23: −0.0102 REMARK 3 L TENSOR REMARK 3 L11: 0.0034L22: 0.2021 REMARK 3 L33: 0.0378 L12: 0.0063 REMARK 3 L13: 0.0031 L23:−0.0919 REMARK 3 S TENSOR REMARK 3 S11: 0.0075 S12: −0.0003 S13: −0.0248REMARK 3 S21: −0.0899 S22: 0.0437 S23: −0.0012 REMARK 3 S31: −0.0422S32: 0.1216 S33: 0.0477 REMARK 3 CRYST1 43.018 4.849 19.774 90.00 92.1290.00 C 1 2 1 SCALE1 0.023246 0.000000 0.000861 0.00000 SCALE2 0.0000000.206228 0.000000 0.00000 SCALE3 0.000000 0.000000 0.050606 0.00000 ATOM1 N THR Z 1 1.586 −0.480 4.758 1.00 5.90 N ANISOU 1 N THR Z 1 761 678805 101 −37 58 N ATOM 2 CA THR Z 1 2.773 0.083 5.366 1.00 4.89 C ANISOU2 CA THR Z 1 618 556 685 109 −42 48 C ATOM 3 C THR Z 1 4.028 −0.5254.751 1.00 4.69 C ANISOU 3 C THR Z 1 583 552 645 117 −45 21 C ATOM 4 OTHR Z 1 4.118 −1.734 4.602 1.00 4.25 O ANISOU 4 O THR Z 1 514 503 596129 −53 20 O ATOM 5 CB THR Z 1 2.767 −0.177 6.879 1.00 10.67 C ANISOU 5CB THR Z 1 1337 1315 1404 117 −36 39 C ATOM 6 OG1 THR Z 1 1.507 0.2357.426 1.00 12.86 O ANISOU 6 OG1 THR Z 1 1629 1577 1680 104 −37 45 O ATOM7 CG2 THR Z 1 3.887 0.582 7.558 1.00 6.79 C ANISOU 7 CG2 THR Z 1 813 838927 116 −24 34 C ATOM 8 N ILE Z 2 4.974 0.322 4.359 1.00 3.60 N ANISOU 8N ILE Z 2 454 437 477 89 −22 0 N ATOM 9 CA ILE Z 2 6.260 −0.149 3.8521.00 4.86 C ANISOU 9 CA ILE Z 2 602 629 613 86 −9 −27 C ATOM 10 C ILE Z2 7.394 0.432 4.683 1.00 5.86 C ANISOU 10 C ILE Z 2 706 797 724 71 17−44 C ATOM 11 O ILE Z 2 7.493 1.644 4.841 1.00 4.81 O ANISOU 11 O ILE Z2 584 666 578 46 32 −46 O ATOM 12 CB ILE Z 2 6.489 0.275 2.388 1.00 4.24C ANISOU 12 CB ILE Z 2 558 541 511 64 −4 −37 C ATOM 13 CG1 ILE Z 2 5.349−0.210 1.492 1.00 5.28 C ANISOU 13 CG1 ILE Z 2 719 631 658 75 −31 −19 CATOM 14 CG2 ILE Z 2 7.836 −0.232 1.890 1.00 6.18 C ANISOU 14 CG2 ILE Z 2792 822 734 62 12 −64 C ATOM 15 CD1 ILE Z 2 5.480 0.241 0.054 1.00 6.81C ANISOU 15 CD1 ILE Z 2 950 811 828 54 −28 −28 C ATOM 16 N ILE Z 3 8.248−0.436 5.205 1.00 3.28 N ANISOU 16 N ILE Z 3 346 502 398 86 21 −58 NATOM 17 CA ILE Z 3 9.450 0.006 5.891 1.00 2.54 C ANISOU 17 CA ILE Z 3229 449 289 72 44 −76 C ATOM 18 C ILE Z 3 10.639 −0.630 5.179 1.00 3.98C ANISOU 18 C ILE Z 3 400 659 453 72 55 −99 C ATOM 19 O ILE Z 3 10.711−1.845 5.063 1.00 2.86 O ANISOU 19 O ILE Z 3 243 520 322 97 43 −100 OATOM 20 CB ILE Z 3 9.414 −0.400 7.376 1.00 4.84 C ANISOU 20 CB ILE Z 3487 754 599 91 40 −69 C ATOM 21 CG1 ILE Z 3 8.220 0.261 8.067 1.00 4.33C ANISOU 21 CG1 ILE Z 3 436 660 551 92 31 −45 C ATOM 22 CG2 ILE Z 310.697 0.002 8.080 1.00 2.84 C ANISOU 22 CG2 ILE Z 3 221 529 331 70 56−80 C ATOM 23 CD1 ILE Z 3 7.800 −0.407 9.356 1.00 8.14 C ANISOU 23 CD1ILE Z 3 909 1126 1058 102 19 −27 C ATOM 24 N THR Z 4 11.553 0.199 4.6861.00 3.85 N ANISOU 24 N THR Z 4 391 661 411 44 77 −116 N ATOM 25 CA THRZ 4 12.701 −0.291 3.932 1.00 4.67 C ANISOU 25 CA THR Z 4 487 790 498 4291 −137 C ATOM 26 C THR Z 4 14.018 0.243 4.471 1.00 6.53 C ANISOU 26 CTHR Z 4 710 1042 729 20 101 −138 C ATOM 27 O THR Z 4 14.193 1.447 4.5791.00 6.74 O ANISOU 27 O THR Z 4 748 1068 746 −4 111 −138 O ATOM 28 CBTHR Z 4 12.604 0.142 2.459 1.00 6.65 C ANISOU 28 CB THR Z 4 776 1022 72925 96 −142 C ATOM 29 CG1 THR Z 4 11.403 −0.379 1.887 1.00 7.91 O ANISOU29 CG1 THR Z 4 961 1142 903 41 71 −125 O ATOM 30 CG2 THR Z 4 13.797−0.363 1.668 1.00 9.32 C ANISOU 30 CG2 THR Z 4 1109 1379 1053 22 109−159 C ATOM 31 N LEU Z 5 14.953 −0.649 4.775 1.00 4.74 N ANISOU 31 N LEUZ 5 463 829 511 29 96 −140 N ATOM 32 CA LEU Z 5 16.306 −0.228 5.093 1.007.05 C ANISOU 32 CA LEU Z 5 745 1136 796 12 105 −146 C ATOM 33 C LEU Z 517.251 −0.915 4.121 1.00 8.18 C ANISOU 33 C LEU Z 5 887 1289 933 14 113−156 C ATOM 34 O LEU Z 5 17.302 −2.135 4.056 1.00 9.26 O ANISOU 34 O LEUZ 5 1013 1426 1079 34 104 −156 O ATOM 35 CB LEU Z 5 16.654 −0.594 6.5321.00 5.48 C ANISOU 35 CB LEU Z 5 527 942 611 19 93 −137 C ATOM 36 CG LEUZ 5 15.814 0.143 7.577 1.00 10.92 C ANISOU 36 CG LEU Z 5 1220 1622 130716 87 −126 C ATOM 37 CD1 LEU Z 5 14.477 −0.548 7.783 1.00 11.06 C ANISOU37 CD1 LEU Z 5 1240 1621 1340 39 74 −114 C ATOM 38 CD2 LEU Z 5 16.5780.252 8.883 1.00 16.68 C ANISOU 38 CD2 LEU Z 5 1938 2359 2040 12 83 −123C ATOM 39 N GLU Z 6 18.017 −0.137 3.371 1.00 6.37 N ANISOU 39 N GLU Z 6668 1065 689 −6 128 −164 N ATOM 40 CA GLU Z 6 18.866 −0.744 2.353 1.007.06 C ANISOU 40 CA GLU Z 6 755 1157 769 −3 139 −173 C ATOM 41 C GLU Z 620.226 −1.181 2.865 1.00 10.47 C ANISOU 41 C GLU Z 6 1163 1608 1206 −3141 −176 C ATOM 42 O GLU Z 6 20.778 −2.133 2.338 1.00 10.97 O ANISOU 42O GLU Z 6 1221 1676 1270 9 144 −181 O ATOM 43 CB GLU Z 6 19.030 0.1571.128 1.00 6.61 C ANISOU 43 CB GLU Z 6 725 1094 693 −22 154 −180 C ATOM44 CG GLU Z 6 19.460 −0.607 −0.118 1.00 8.76 C ANISOU 44 CG GLU Z 6 10091365 957 −14 164 −188 C ATOM 45 CD GLU Z 6 19.538 0.284 −1.341 1.00 9.29C ANISOU 45 CD GLU Z 6 1106 1420 1005 −32 177 −192 C ATOM 46 OE1 GLU Z 619.525 1.503 −1.155 1.00 9.75 O ANISOU 46 OE1 GLU Z 6 1171 1476 1059 −53180 −189 O ATOM 47 OE2 GLU Z 6 19.597 −0.234 −2.473 1.00 8.35 O ANISOU47 OE2 GLU Z 6 1006 1293 875 −25 184 −197 O ATOM 48 OXT GLU Z 6 20.577−0.596 3.827 1.00 10.37 O ANISOU 48 OXT GLU Z 6 1140 1602 1196 −13 137−173 O TER HETATM 49 ZN ZN B 1 1.135 0.108 2.815 1.00 6.38 ZN ANISOU 49ZN ZN B 1 854 704 866 82 −52 60 ZN TER HETATM 50 O HOH A 1 −1.382 −1.0295.472 1.00 14.91 O ANISOU 50 O HOH A 1 1900 1800 1964 82 −56 65 O HETATM51 O HOH A 2 10.560 2.460 0.798 1.00 26.28 O ANISOU 51 O HOH A 2 33573428 3199 −21 86 −116 O TER END

TABLE 4 REMARK Date 2012-02-15 Time 20:23:19 PST −0800 (1329366199.79 s)REMARK PHENIX refinement REMARK REMARK ****************** INPUT FILESAND LABELS *************** REMARK Reflections: REMARK file name: 17e.mtzREMARK labels: [‘IMEAN, SIGIMEAN’] REMARK R-free flags: REMARK filename: 17e.mtz REMARK label: FreeR_flag REMARK test_flag_value: 0 REMARKModel file name(s): REMARK/home/absoriaga/APS/L7E/1.72A/build009_001-coot-1.pdb REMARK REMARK******************** REFINEMENT SUMMARY: QUICK FACTS ********** REMARKStart: r_work = 0.1662 r_free = 0.1917 bonds = 0.007 angles = 1.078REMARK Final: r_work = 0.1626 r_free = 0.1919 bonds = 0.007 angles =1.080 REMARK*******************************************************************REMARK REMARK ****************** REFINEMENT STATISTICS STEP BY STEP******* REMARK leading digit, like 1_, means number of macro-cycleREMARK 0 : statistics at the very beginning when nothing is done yetREMARK 1 s: bulk solvent correction and/or (anisotropic) scaling REMARK1 z: refinement of coordinates REMARK--------------------------------------------------------------- REMARKR-factors, x-ray target values and norm of gradient of x-ray targetREMARK stage r-work r-free xray_target_w xray_target_t REMARK 0 : 0.17710.1905 3.652480e−01 4.073357e−01 REMARK 1_bss: 0.1662 0.19172.117160e−01 3.975473e−01 REMARK 1_ohs: 0.1662 0.1917 2.117160e−013.975473e−01 REMARK 1_xyz: 0.1619 0.1890 1.754450e−01 3.580521e−01REMARK 1_adp: 0.1674 0.1960 1.964973e−01 3.683984e−01 REMARK 2_bss:0.1690 0.2055 2.335866e−01 4.382616e−01 REMARK 2_ohs: 0.1690 0.20552.335866e−01 4.382616e−01 REMARK 2_xyz: 0.1667 0.2061 2.401298e−014.654830e−01 REMARK 2_adp: 0.1654 0.2035 2.351643e−01 4.720430e−01REMARK 3_bss: 0.1651 0.1920 2.011024e−01 3.900795e−01 REMARK 3_ohs:0.1651 0.1920 2.011024e−01 3.900795e−01 REMARK 3_xyz: 0.1648 0.19011.963632e−01 3.805261e−01 REMARK 3_adp: 0.1648 0.1907 1.960629e−013.791067e−01 REMARK 3_bss: 0.1626 0.1919 1.911754e−01 3.915615e−01REMARK 3_ohs: 0.1626 0.1919 1.911754e−01 3.915615e−01 REMARK--------------------------------------------------------------- REMARKstage k_sol b_sol b11 b22 b33 b12 b13 b23 REMARK 0 : 0.600 80.084 1.1420.456 −1.597 −0.206 0.548 −3.160 REMARK 1_bss: 0.600 39.857 1.373 0.376−1.749 −0.196 0.551 −3.115 REMARK 1_ohs: 0.600 39.857 1.373 0.376 −1.749−0.196 0.551 −3.115 REMARK 1_xyz: 0.600 39.857 1.373 0.376 −1.749 −0.1960.551 −3.115 REMARK 1_adp: 0.600 39.857 1.373 0.376 −1.749 −0.196 0.551−3.115 REMARK 2_bss: 0.600 37.717 1.451 0.387 −1.837 −0.208 0.596 −3.087REMARK 2_ohs: 0.600 37.717 1.451 0.387 −1.837 −0.208 0.596 −3.087 REMARK2_xyz: 0.600 37.717 1.451 0.387 −1.837 −0.208 0.596 −3.087 REMARK 2_adp:0.600 37.717 1.451 0.387 −1.837 −0.208 0.596 −3.087 REMARK 3_bss: 0.60035.678 1.451 0.387 −1.837 −0.208 0.596 −3.087 REMARK 3_ohs: 0.600 35.6781.451 0.387 −1.837 −0.208 0.596 −3.087 REMARK 3_xyz: 0.600 35.678 1.4510.387 −1.837 −0.208 0.596 −3.087 REMARK 3_adp: 0.600 35.678 1.451 0.387−1.837 −0.208 0.596 −3.087 REMARK 3_bss: 0.600 30.131 1.451 0.387 −1.837−0.208 0.596 −3.087 REMARK 3_ohs: 0.600 30.131 1.451 0.387 −1.837 −0.2080.596 −3.087 REMARK--------------------------------------------------------------- REMARKstage <pher>fom alpha beta REMARK 0 : 26.144 0.8035 0.0979 0.313 REMARK1_bss: 26.758 0.7974 0.0981 0.315 REMARK 1_ohs: 26.758 0.7974 0.09810.315 REMARK 1_xyz: 25.873 0.8067 0.0970 0.291 REMARK 1_adp: 25.8490.8071 0.0970 0.294 REMARK 2_bss: 27.844 0.7856 0.0966 0.340 REMARK2_ohs: 27.844 0.7856 0.0966 0.340 REMARK 2_xyz: 28.600 0.7770 0.09670.358 REMARK 2_adp: 28.733 0.7755 0.0978 0.362 REMARK 3_bss: 26.4070.8007 0.0989 0.305 REMARK 3_ohs: 26.407 0.8007 0.0989 0.305 REMARK3_xyz: 26.098 0.8041 0.0989 0.299 REMARK 3_adp: 25.979 0.8054 0.09880.297 REMARK 3_bss: 26.185 0.8034 0.0990 0.304 REMARK 3_ohs: 26.1850.8034 0.0990 0.304 REMARK--------------------------------------------------------------- REMARKstage angl bond chir dihe plan repu geom_target REMARK 0 : 1.078 0.0070.059 18.680 0.003 4.264 6.7991e−02 REMARK 1_bss: 1.078 0.007 0.05918.680 0.003 4.264 6.7991e−02 REMARK 1_ohs: 1.078 0.007 0.059 18.6800.003 4.264 6.7991e−02 REMARK 1_xyz: 1.169 0.007 0.070 17.979 0.0044.264 7.1164e−02 REMARK 1_adp: 1.169 0.007 0.070 17.979 0.004 4.2647.1164e−02 REMARK 2_bss: 1.169 0.007 0.070 17.979 0.004 4.264 7.1164e−02REMARK 2_ohs: 1.169 0.007 0.070 17.979 0.004 4.264 7.1164e−02 REMARK2_xyz: 1.090 0.007 0.064 18.389 0.003 4.263 6.8180e−02 REMARK 2_adp:1.090 0.007 0.064 18.389 0.003 4.263 6.8180e−02 REMARK 3_bss: 1.0900.007 0.064 18.389 0.003 4.263 6.8180e−02 REMARK 3_ohs: 1.090 0.0070.064 18.389 0.003 4.263 6.8180e−02 REMARK 3_xyz: 1.080 0.007 0.06118.346 0.003 4.263 6.7329e−02 REMARK 3_adp: 1.080 0.007 0.061 18.3460.003 4.263 6.7329e−02 REMARK 3_bss: 1.080 0.007 0.061 18.346 0.0034.263 6.7329e−02 REMARK 3_ohs: 1.080 0.007 0.061 18.346 0.003 4.2636.7329e−02 REMARK--------------------------------------------------------------- REMARKMaximal deviations: REMARK stage angl bond chi r dihe plan repu |grad|REMARK 0 : 4.404 0.026 0.099 64.798 0.006 2.545 2.5455e−01 REMARK 1_bss:4.404 0.026 0.099 64.798 0.006 2.545 2.5455e−01 REMARK 1_ohs: 4.4040.026 0.099 64.798 0.006 2.545 2.5455e−01 REMARK 1_xyz: 3.519 0.0240.127 61.369 0.007 2.579 2.8547e−01 REMARK 1_adp: 3.519 0.024 0.12761.369 0.007 2.579 2.8547e−01 REMARK 2_bss: 3.519 0.024 0.127 61.3690.007 2.579 2.8547e−01 REMARK 2_ohs: 3.519 0.024 0.127 61.369 0.0072.579 2.8547e−01 REMARK 2_xyz: 2.977 0.027 0.123 64.073 0.006 2.5912.4811e−01 REMARK 2_adp: 2.977 0.027 0.123 64.073 0.006 2.591 2.4811e−01REMARK 3_bss: 2.977 0.027 0.123 64.073 0.006 2.591 2.4811e−01 REMARK3_ohs: 2.977 0.027 0.123 64.073 0.006 2.591 2.4811e−01 REMARK 3_xyz:3.213 0.022 0.113 63.776 0.005 2.591 2.4147e−01 REMARK 3_adp: 3.2130.022 0.113 63.776 0.005 2.591 2.4147e−01 REMARK 3_bss: 3.213 0.0220.113 63.776 0.005 2.591 2.4147e−01 REMARK 3_ohs: 3.213 0.022 0.11363.776 0.005 2.591 2.4147e−01 REMARK--------------------------------------------------------------- REMARK|-----overall-----|---macromolecule----|------solvent-------| REMARKstage b_max b_min b_ave b_max b_min b_ave b_max b_min b_ave REMARK 0 :43.34 4.47 13.98 43.34 4.47 13.89 27.13 10.20 15.93 REMARK 1_bss: 43.734.86 14.37 43.73 4.86 14.27 27.52 10.59 16.31 REMARK 1_ohs: 43.73 4.8614.37 43.73 4.86 14.27 27.52 10.59 16.31 REMARK 1_xyz: 43.73 4.86 14.3743.73 4.86 14.27 27.52 10.59 16.31 REMARK 1_adp: 34.22 6.51 13.79 34.226.51 13.65 23.32 12.30 16.48 REMARK 2_bss: 34.28 6.57 13.85 34.28 6.5713.71 23.39 12.36 16.54 REMARK 2_ohs: 34.28 6.57 13.85 34.28 6.57 13.7123.39 12.36 16.54 REMARK 2_xyz: 34.28 6.57 13.85 34.28 6.57 13.71 23.3912.36 16.54 REMARK 2_adp: 35.29 6.18 14.27 35.29 6.18 14.08 31.25 10.4417.92 REMARK 3_bss: 35.29 6.18 14.27 35.29 6.18 14.08 31.25 10.44 17.92REMARK 3_ohs: 35.29 6.18 14.27 35.29 6.18 14.08 31.25 10.44 17.92 REMARK3_xyz: 35.29 6.18 14.27 35.29 6.18 14.08 31.25 10.44 17.92 REMARK 3_adp:35.70 5.88 14.25 35.70 5.88 14.08 31.83 9.77 17.66 REMARK 3_bss: 35.705.88 14.25 35.70 5.88 14.08 31.83 9.77 17.66 REMARK 3_ohs: 35.70 5.8814.25 35.70 5.88 14.08 31.83 9.77 17.66 REMARK--------------------------------------------------------------- REMARKstage Deviation of refined REMARK model from start model REMARK max minmean REMARK 0 : 0.000 0.000 0.000 REMARK 1_bss: 0.000 0.000 0.000 REMARK1_ohs: 0.000 0.000 0.000 REMARK 1_xyz: 0.204 0.016 0.055 REMARK 1_adp:0.204 0.016 0.055 REMARK 2_bss: 0.204 0.016 0.055 REMARK 2_ohs: 0.2040.016 0.055 REMARK 2_xyz: 0.351 0.010 0.060 REMARK 2_adp: 0.351 0.0100.060 REMARK 3_bss: 0.351 0.010 0.060 REMARK 3_ohs: 0.351 0.010 0.060REMARK 3_xyz: 0.336 0.009 0.059 REMARK 3_adp: 0.336 0.009 0.059 REMARK3_bss: 0.336 0.009 0.059 REMARK 3_ohs: 0.336 0.009 0.059 REMARK--------------------------------------------------------------- REMARKMODEL CONTENT. REMARK ELEMENT ATOM RECORD COUNT OCCUPANCY SUM REMARK C40 37.00 REMARK O 15 14.00 REMARK N 7 7.00 REMARK TOTAL 62 58.00 REMARK--------------------------------------------------------------- REMARKr_free_flags.md5.hexdigest 3bd517a07859c6c80cf6f8225f5dfe4a REMARKREMARK IF THIS FILE IS FOR PDB DEPOSITION: REMOVE ALL FROM THIS LINE UP.REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM: PHENIX (phenix.refine:1.7.3_928) REMARK 3 AUTHORS: Adams, Afonine, Chen, Davis, Echols,Gildea, Gopal, REMARK 3 : Grosse-Kunstleve, Headd, Hung, Immormino,Ioerger, McCoy, REMARK 3 : McKee, Moriarty, Pai, Read, Richardson,Richardson, Romo, REMARK 3 : Sacchettini, Sauter, Smith, Storoni,Terwilliger, Zwart REMARK 3 REMARK 3 REFINEMENT TARGET: ML REMARK 3REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH(ANGSTROMS): 1.703 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS): 21.302REMARK 3 MIN(FOBS/SIGMA_FOBS): 2.14 REMARK 3 COMPLETENESS FOR RANGE (%):93.72 REMARK 3 NUMBER OF REFLECTIONS: 507 REMARK 3 NUMBER OF REFLECTIONS(NON-ANOMALOUS): 507 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT.REMARK 3 R VALUE (WORKING + TEST SET): 0.1655 REMARK 3 R VALUE (WORKINGSET): 0.1626 REMARK 3 FREE R VALUE: 0.1919 REMARK 3 FREE R VALUE TESTSET SIZE (%): 9.86 REMARK 3 FREE R VALUE TEST SET COUNT: 50 REMARK 3REMARK 3 FIT TO DATA USED IN REFINEMENT (IN BINS). REMARK 3 BINRESOLUTION RANGE COMPL. NWORK NFREE RWORK RFREE REMARK 3 121.3038-1.7025 0.94 457 50 0.1626 0.1919 REMARK 3 REMARK 3 BULK SOLVENTMODELLING. REMARK 3 METHOD USED: FLAT BULK SOLVENT MODEL REMARK 3SOLVENT RADIUS: 1.30 REMARK 3 SHRINKAGE RADIUS: 1.11 REMARK 3 GRID STEPFACTOR: 4.00 REMARK 3 K_SOL: 0.600 REMARK 3 B_SOL: 30.131 REMARK 3REMARK 3 ERROR ESTIMATES. REMARK 3 COORDINATE ERROR (MAXIMUM-LIKELIHOODBASED): 0.06 REMARK 3 PHASE ERROR (DEGREES, MAXIMUM-LIKELIHOOD BASED):26.18 REMARK 3 REMARK 3 OVERALL SCALE FACTORS. REMARK 3 SCALE =SUM(|F_OBS|*|F_MODEL|)/SUM(|F_MODEL|**2): 0.0995 REMARK 3 ANISOTROPICSCALE MATRIX ELEMENTS (IN CARTESIAN BASIS). REMARK 3 B11: 1.4505 REMARK3 B22: 0.3869 REMARK 3 B33: −1.8374 REMARK 3 B12: −0.2078 REMARK 3 B13:0.5956 REMARK 3 B23: −3.0866 REMARK 3 REMARK 3 R FACTOR FORMULA. REMARK3 R = SUM(||F_OBS|−SCALE*|F_MODEL||)/SUM(|F_OBS|) REMARK 3 REMARK 3TOTAL MODEL STRUCTURE FACTOR (F_MODEL). REMARK 3 F_MODEL = FB_CART *(F_CALC_ATOMS + F_BULK) REMARK 3 F_BULK = K_SOL * EXP(−B_SOL * S**2/4) *F_MASK REMARK 3 F_CALC_ATOMS = ATOMIC MODEL STRUCTURE FACTORS REMARK 3FB_CART = EXP(−H(t) * A(−1) * B * A(−1t) * H) REMARK 3 A =orthogonalization matrix, H = MILLER INDEX REMARK 3 (t) = TRANSPOSE,(−1) = INVERSE REMARK 3 REMARK 3 STRUCTURE FACTORS CALCULATIONALGORITHM: FFT REMARK 3 REMARK 3 DEVIATIONS FROM IDEAL VALUES. REMARK 3RMSD MAX COUNT REMARK 3 BOND: 0.007 0.022 61 REMARK 3 ANGLE: 1.080 3.21385 REMARK 3 CHIRALITY: 0.061 0.113 15 REMARK 3 PLANARITY: 0.003 0.005 9REMARK 3 DIHEDRAL: 18.346 63.776 24 REMARK 3 MIN NONBONDED DISTANCE:2.591 REMARK 3 REMARK 3 MOLPROBITY STATISTICS. REMARK 3 ALL-ATOMCLASHSCORE: 0.00 REMARK 3 RAMACHANDRAN PLOT: REMARK 3 OUTLIERS: 0.00%REMARK 3 ALLOWED: 0.00% REMARK 3 FAVORED: 100.00% REMARK 3 ROTAMEROUTLIERS: 0.00% REMARK 3 CBETA DEVIATIONS: 0 REMARK 3 REMARK 3 ATOMICDISPLACEMENT PARAMETERS. REMARK 3 WILSON B: 12.73 REMARK 3RMS(B_ISO_OR_EQUIVALENT_BONDED): 2.28 REMARK 3 ATOMS NUMBER OF ATOMSREMARK 3 ISO. ANISO. REMARK 3 ALL: 62 62 REMARK 3 ALL (NO H): 62 62REMARK 3 SOLVENT: 3 3 REMARK 3 NON-SOLVENT: 59 59 REMARK 3 HYDROGENS: 00 REMARK 3 REMARK 3 TLS DETAILS. REMARK 3 NUMBER OF TLS GROUPS: 1 REMARK3 ORIGIN: CENTER OF MASS REMARK 3 TLS GROUP: 1 REMARK 3 SELECTION: allREMARK 3 ORIGIN FOR THE GROUP (A): 0.1185 6.8484 9.0224 REMARK 3 TTENSOR REMARK 3 T11: 0.0582 T22: 0.0750 REMARK 3 T33: 0.0849 T12: 0.0099REMARK 3 T13: 0.0029 T23: 0.0090 REMARK 3 L TENSOR REMARK 3 L11: 2.3157L22: 4.0221 REMARK 3 L33: 4.8813 L12: −0.4063 REMARK 3 L13: −1.1355 L23:1.8148 REMARK 3 S TENSOR REMARK 3 S11: 0.0087 S12: −0.0689 S13: −0.0102REMARK 3 S21: 0.1493 S22: 0.2397 S23: −0.0164 REMARK 3 S31: −0.1178 S32:0.0395 S33: −0.1915 REMARK 3 CRYST1 4.811 12.599 21.340 86.59 89.2979.15 P 1 SCALE1 0.207857 −0.039846 −0.000241 0.00000 SCALE2 0.0000000.080817 −0.004715 0.00000 SCALE3 0.000000 0.000000 0.046944 0.00000ATOM 1 N LEU Z 1 0.068 1.128 −2.181 1.00 15.58 N ANISOU 1 N LEU Z 1 18692159 1891 −379 −166 −311 N ATOM 2 CA LEU Z 1 −0.127 0.804 −0.768 1.0013.08 C ANISOU 2 CA LEU Z 1 1469 1787 1714 −344 −176 −260 C ATOM 3 C LEUZ 1 0.557 1.846 0.111 1.00 12.34 C ANISOU 3 C LEU Z 1 1366 1679 1644−279 −114 −206 C ATOM 4 O LEU Z 1 1.781 1.952 0.130 1.00 13.64 O ANISOU4 O LEU Z 1 1530 1824 1827 −273 −43 −284 O ATOM 5 CB LEU Z 1 0.402−0.599 −0.458 1.00 12.49 C ANISOU 5 CB LEU Z 1 1398 1613 1735 −354 −160−349 C ATOM 6 CG LEU Z 1 −0.073 −1.318 0.805 1.00 16.04 C ANISOU 6 CGLEU Z 1 1832 1974 2288 −335 −172 −291 C ATOM 7 CD1 LEU Z 1 0.293 −2.7940.696 1.00 16.64 C ANISOU 7 CD1 LEU Z 1 1983 1918 2423 −348 −154 −382 CATOM 8 CD2 LEU Z 1 0.530 −0.711 2.067 1.00 13.96 C ANISOU 8 CD2 LEU Z 11552 1694 2057 −229 −151 −224 C ATOM 9 N THR Z 2 −0.245 2.601 0.848 1.009.66 N ANISOU 9 N THR Z 2 1001 1359 1311 −237 −137 −97 N ATOM 10 CA THRZ 2 0.258 3.731 1.615 1.00 9.85 C ANISOU 10 CA THR Z 2 1039 1364 1338−192 −78 −58 C ATOM 11 C THR Z 2 −0.369 3.689 2.996 1.00 9.29 C ANISOU11 C THR Z 2 920 1277 1333 −139 −99 14 C ATOM 12 O THR Z 2 −1.588 3.5753.128 1.00 10.23 O ANISOU 12 O THR Z 2 997 1428 1461 −132 −136 80 O ATOM13 CB THR Z 2 −0.098 5.087 0.930 1.00 12.90 C ANISOU 13 CB THR Z 2 15181766 1616 −175 −48 11 C ATOM 14 OG1 THR Z 2 0.500 5.144 −0.374 1.0013.73 O ANISOU 14 OG1 THR Z 2 1716 1876 1624 −232 0 −46 O ATOM 15 CG2THR Z 2 0.400 6.264 1.758 1.00 11.80 C ANISOU 15 CG2 THR Z 2 1419 15731490 −154 36 33 C ATOM 16 N ILE Z 3 0.474 3.750 4.022 1.00 6.76 N ANISOU16 N ILE Z 3 595 923 1051 −104 −75 −16 N ATOM 17 C ILE Z 3 0.661 5.0066.102 1.00 6.68 C ANISOU 17 C ILE Z 3 605 896 1039 −19 −41 27 C ATOM 18O ILE Z 3 1.887 5.178 6.075 1.00 7.92 O ANISOU 18 O ILE Z 3 742 10641205 −36 −33 −81 O ATOM 19 CA ILE Z 3 0.020 3.798 5.405 1.00 7.02 CANISOU 19 CA ILE Z 3 625 937 1106 −48 −79 49 C ATOM 20 CB ILE Z 3 0.3982.499 6.141 1.00 5.88 C ANISOU 20 CB ILE Z 3 498 739 998 −12 −112 30 CATOM 21 CG1 ILE Z 3 −0.197 1.292 5.414 1.00 7.70 C ANISOU 21 CG1 ILE Z 3733 931 1261 −74 −124 28 C ATOM 22 CG2 ILE Z 3 −0.022 2.568 7.617 1.008.38 C ANISOU 22 CG2 ILE Z 3 862 1029 1293 49 −99 106 C ATOM 23 CD1 ILEZ 3 0.383 −0.041 5.862 1.00 10.12 C ANISOU 23 CD1 ILE Z 3 1113 1135 1598−27 −141 −2 C ATOM 24 N ILE Z 4 −0.170 5.849 6.712 1.00 8.44 N ANISOU 24N ILE Z 4 855 1114 1239 17 −8 104 N ATOM 25 CA ILE Z 4 0.310 7.046 7.4041.00 7.11 C ANISOU 25 CA ILE Z 4 735 924 1043 31 42 71 C ATOM 26 C ILE Z4 −0.366 7.145 8.763 1.00 9.16 C ANISOU 26 C ILE Z 4 1019 1178 1284 10054 127 C ATOM 27 O ILE Z 4 −1.596 7.044 8.848 1.00 8.49 O ANISOU 27 OILE Z 4 916 1102 1207 133 78 218 O ATOM 28 CB ILE Z 4 −0.014 8.320 6.5911.00 8.14 C ANISOU 28 CB ILE Z 4 940 1014 1138 18 112 105 C ATOM 29 CG1ILE Z 4 0.721 8.307 5.245 1.00 11.61 C ANISOU 29 CG1 ILE Z 4 1404 14491560 −64 136 51 C ATOM 30 CG2 ILE Z 4 0.332 9.585 7.377 1.00 8.29 CANISOU 30 CG2 ILE Z 4 1043 971 1135 18 190 66 C ATOM 31 CD1 ILE Z 40.132 9.280 4.232 1.00 13.32 C ANISOU 31 CD1 ILE Z 4 1748 1614 1700 −43187 133 C ATOM 32 N THR Z 5 0.410 7.339 9.826 1.00 6.75 N ANISOU 32 NTHR Z 5 745 875 946 121 39 57 N ATOM 33 CA THR Z 5 −0.180 7.546 11.1521.00 8.77 C ANISOU 33 CA THR Z 5 1064 1122 1145 187 68 102 C ATOM 34 CTHR Z 5 0.418 8.797 11.800 1.00 10.69 C ANISOU 34 C THR Z 5 1368 13521343 179 100 5 C ATOM 35 O THR Z 5 1.642 8.947 11.834 1.00 11.07 OANISOU 35 O THR Z 5 1384 1431 1390 132 48 −131 O ATOM 36 CB THR Z 50.030 6.323 12.090 1.00 10.48 C ANISOU 36 CB THR Z 5 1320 1349 1315 2445 121 C ATOM 37 OG1 THR Z 5 1.406 6.224 12.461 1.00 13.87 O ANISOU 37OG1 THR Z 5 1741 1820 1710 274 −97 −3 0 ATOM 38 CG2 THR Z 5 −0.409 5.02111.436 1.00 10.34 C ANISOU 38 CG2 THR Z 5 1271 1306 1351 221 −8 189 CATOM 39 N LEU Z 6 −0.446 9.696 12.278 1.00 12.10 N ANISOU 39 N LEU Z 61617 1488 1493 217 192 50 N ATOM 40 C LEU Z 6 −0.524 10.931 14.393 1.0014.83 C ANISOU 40 C LEU Z 6 2136 1804 1694 281 272 −38 C ATOM 41 O LEU Z6 −1.656 10.521 14.660 1.00 14.90 O ANISOU 41 O LEU Z 6 2144 1819 1699347 331 79 O ATOM 42 CD1 LEU Z 6 0.469 11.983 9.998 1.00 16.40 C ANISOU42 CD1 LEU Z 6 2268 1865 2100 55 338 −42 C ATOM 43 CD2 LEU Z 6 −0.32614.207 10.832 1.00 17.47 C ANISOU 43 CD2 LEU Z 6 2662 1793 2182 133 528−40 C ATOM 44 CA ALEU Z 6 −0.015 10.912 12.963 0.50 14.01 C ANISOU 44 CAALEU Z 6 1950 1686 1686 202 244 −51 C ATOM 45 CB ALEU Z 6 −0.561 12.15812.261 0.50 14.80 C ANISOU 45 CB ALEU Z 6 2124 1682 1819 202 359 −19 CATOM 46 CG ALEU Z 6 0.295 12.867 11.213 0.50 18.60 C ANISOU 46 CG ALEU Z6 2642 2089 2334 89 398 −91 C ATOM 47 CA BLEU Z 6 −0.015 10.912 12.9630.50 14.11 C ANISOU 47 CA BLEU Z 6 1963 1699 1699 202 244 −51 C ATOM 48CB BLEU Z 6 −0.561 12.158 12.261 0.50 14.85 C ANISOU 48 CB BLEU Z 6 21301688 1825 202 359 −19 C ATOM 49 CG BLEU Z 6 0.295 12.867 11.213 0.5018.60 C ANISOU 49 CG BLEU Z 6 2642 2089 2334 89 398 −91 C ATOM 50 N GLUZ 7 0.304 11.423 15.303 1.00 16.19 N ANISOU 50 N GLU Z 7 2376 1992 1785261 239 −177 N ATOM 51 CA GLU Z 7 −0.131 11.710 16.667 1.00 21.28 CANISOU 51 CA GLU Z 7 3145 2639 2303 331 284 −189 C ATOM 52 C GLU Z 70.706 12.866 17.251 1.00 26.95 C ANISOU 52 C GLU Z 7 3942 3336 2963 264284 −387 C ATOM 53 O GLU Z 7 1.715 13.280 16.656 1.00 23.82 O ANISOU 53O GLU Z 7 3479 2938 2632 147 244 −521 O ATOM 54 CB GLU Z 7 −0.080 10.46117.558 1.00 21.58 C ANISOU 54 CB GLU Z 7 3220 2754 2224 408 196 −134 CATOM 55 CG GLU Z 7 1.286 9.867 17.714 1.00 25.98 C ANISOU 55 CG GLU Z 73733 3401 2738 411 3 −247 C ATOM 56 CD GLU Z 7 1.279 8.604 18.550 1.0030.97 C ANISOU 56 CD GLU Z 7 4464 4072 3233 533 −84 −159 C ATOM 57 OE1GLU Z 7 0.937 8.687 19.747 1.00 30.45 O ANISOU 57 OE1 GLU Z 7 4567 40102992 603 −53 −141 O ATOM 58 OE2 GLU Z 7 1.617 7.528 18.011 1.00 35.70 OANISOU 58 OE2 GLU Z 7 5002 4678 3883 565 −171 −105 O ATOM 59 OXT GLU Z 70.405 13.433 18.308 1.00 28.69 O ANISOU 59 OXT GLU Z 7 4293 3537 3070304 342 −438 O TER 60 GLU Z 7 HETATM 60 O HOH A 1 −2.703 7.785 14.6921.00 9.77 O ANISOU 60 O HOH A 1 1411 1229 1073 352 306 277 O HETATM 62 OHOH A 2 1.726 3.935 14.170 1.00 31.83 O ANISOU 62 O HOH A 2 4220 40523822 494 −238 95 O TER 63 HOH A 2 END

Table 5 shows statistics of X-ray data collection and refinement for thecrystal structures of the p53 segments. Table 5 discloses “LTIITLE” asSEQ ID NO: 21 and “TIITLE” as SEQ ID NO: 20.

TABLE 5 252-LTIITLE-258 253-TIITLE-258 Crystal parameters Space group P1C2 Cell dimensions a, b, c (Å) 4.81, 12.60, 21.34 43.02, 4.85, 19.77 a.β, γ (°) 86.59, 89.29, 79.15 90, 92.12, 90 Molecules in 1 1 AsymmetricUnit Data collection Synchrotron beamline APS (24-ID-E) APS (24-ID-E)Wavelength (Å) 0.9792 0.9792 Resolution range (Å) 1.70 1.58 UniqueReflections 507 635 Overall Redundancy  3.1 (2.6)^(a) 4.0 (3.0)Completeness (%) 97.0 (91.4) 96.5 (87.7) R_(merge) (%)^(b)  9.6 (50.5)11.4 (32.9) <|/σ|> 10.6 (2.9)  8.9 (4.1) Refinement Resolution (A)21.30-1.70 21.49-1.58 R_(work) (%)^(c) 16.2 16.4 R_(free) (%)^(d) 19.219.3 No. atoms Protein 59 48 Ligand/ion 0 1 Water 2 2 Overall B-factors12.7 3.1 R.m.s. deviation Bond length (Å) 0.007 0.009 Bond angle (°)1.080 1.861 ^(a)Values in parentheses correspond to the highestresolution shell ^(b)R_(merge) = Σ|/ − </>|/Σ/ ^(c)R_(work) = Σ|F_(o) −F_(c)|/Σ F_(o) ^(d)R_(free) = Σ|F_(o) − F_(c)|/Σ F_(o), calculated usinga random set containing reflections that were not included throughoutstructure refinement

The inventors applied their Rosetta-based method (Sievers et al, Nature,2011) to design inhibitors that disrupt p53 aggregation, using thep53₂₅₂₋₂₅₈ structure as a template. In other embodiments of theinvention, the p53₂₅₃₋₂₅₈ structure is used as a template to designinhibitors.

Table 1, shown earlier in this application, shows a list of 16representative sequences obtained by this method.

Table 6 shows the calculated properties of a selection of inhibitors.

TABLE 6 Aggregation propensities and capping energies of the designedinhibitors. Capping energy^(b) Single Sheet Triple Sheet Zipper relativerelative energy^(a) absolute to absolute to (kcal/mol) (kcal/mol)

(kcal/mol)

LTIITLE (native) −26.2 −42.2 0.0 −86.2 0.0 LTRITLE −18.2 −40.5 1.7 −84.61.6 LTRIYLE −19.5 −41.0 1.1 −85.2 1.0 YTRITLE −19.3 −40.3 1.9 −83.5 2.6YTRIYLE −19.8 −41.3 0.8 −85.3 0.9 ETRITLE −19.0 −39.8 2.4 −83.0 3.1LTKITLE −25.5 −41.2 0.9 −84.0 2.2 WTKITLE −24.3^(c) −40.1 2.1 −82.1 4.0YTKITLE −24.1 −40.8 1.3 −82.5 3.6

indicates data missing or illegible when filed

The peptides in Table 6, reading from top to bottom, are represented bySEQ ID NOS 21, 4, 7, 5, 8, 6, 12, 14 and 13.

FIG. 2 shows the INH-1R inhibitor modeled on the p53₂₅₂₋₂₅₈ structure.As evident, the ARG substitution collides with the adjacent sheetefficiently inhibiting new monomers from attaching to the free fiber endand preventing further growth.

The designed inhibitors were synthesized and tested in an in vitroThioflavin T aggregation assay (FIG. 3). The most effective design,INH-1R, delayed the onset of aggregation and lowered the amount ofaggregates present at all concentrations tested, even at a molar ratioof 1 inhibitor to 10 p53 molecules (FIG. 3).

To render the inhibitors cell permeable, the inventors fused thepeptide-inhibitor panel to a nine-residue poly arginine tag through athree-residue linker, of sequence RPI, derived from endogenous p53sequence. To confirm their ability to enter cells, the cell penetratingINH-1R inhibitor was linked to a FITC moiety in order to detect theintracellular localization of the probe by fluorescence microscopy (FIG.4). We treated different cancer cell lines, including but not limited toOVCAR-3, CAOV-3, WiDr, Detroit 562 as well as primary cells derived fromcancer patients with the FITC labeled inhibitor for 24 hours. Afterextensive washes to remove unbound inhibitors, the cells were fixed informaldehyde and p53 was stained using a commercially available p53antibody. As visible in FIG. 4A, the inhibitor was not only able topenetrate the cell membrane, but also to actually enter the nucleus andco-localize with its target, p53. Additionally, the inhibitor was foundco-localized with protein aggregates as stained by the conformationspecific antibody OC (Kayed et al, 2007, FIG. 4B).

The structure-guided, rationally designed p53 amyloid inhibitors of theinvention specifically target those cancer cells bearing p53 moleculeshaving an aberrant conformation (e.g. aggregated or misfolded p53). Wedemonstrated the capability of the inhibitors to halt aggregationprogression in vitro (FIG. 3). We then tested the inhibitor onestablished cancer cell lines as well as on primary cells derived fromserous ovarian cancer patients in order to confirm the clinicalrelevance of our findings. Our inhibitor is designed to specificallytarget those tumor cells expressing an altered misfolded form of p53 andshould have no effect on cells bearing functional, properly folded p53or aggregation-incompetent p53 mutants. To confirm this, we includedseveral controls. Three established cell lines, one bearing WT p53(MCF-7) and two which were previously characterized for their p53aggregation status, one with a non-aggregating mutation (WiDr) and onewith a p53 aggregation prone mutation (Detroit 562), were used asnegative and positive controls. One of the effects of the inhibitor wasto cause re-localization of p53 from the cytosolic compartment to thenucleus (FIG. 5). This effect was not observed in case of the WT p53bearing cells MCF 7 (FIG. 2a ), suggesting that INH-1R is active onlywhen p53 loses is structural integrity.

Another effect of the inhibitor was to cause re-folding of misfolded p53into a WT-like, functional conformation. p53 treated with INH-1R in PA40cells failed to be recognized by the antibody PAb240 which specificallytargets partially unfolded, mutant p53 (FIG. 6), indicating thatre-localization was accompanied by protein re-folding. As a consequenceof p53 maintaining a physiological fold, the levels of p53 proteins intreated cells were decreasing in a dose dependent manner. Properlyfolded p53 is rapidly degraded in cells as a control mechanism.Misfolded/aggregated p53 cannot be efficiently targeted for degradationtherefore protein levels are high in the absence of the inhibitor. Thisis additional evidence of the ability of the INH-1R to generate apopulation of folded p53. Without wishing to be bound by any particularmechanism, it is suggested that this is due to the inhibitor titratingout pre-existing p53 aggregates, by the inhibitor changing theequilibrium between aggregated/misfolded/folded p53, by the inhibitorchaperoning or masking the exposed aggregation prone segment.

INH-1R caused cell death in a dose dependent manner with less than 50%of cancer cells surviving after only 24 hours of treatment with a doseof 10 μM in a 2D culture system as detected by a standard MTS assay(FIG. 7A). The effect of INH-1R is specific since a poly-ARG alone or ascrambled inhibitor sequence did not elicit any effect. Similar resultswere obtained with both cancer cells or primary cells grown in a 3Dculture system. In this case cells were plated in 1:1 mixture ofPrEGM:matrigel. After cell layer solidified, cells were overlaid withwarm PrEGM media containing either the inhibitor or a scrambled controlpeptide at concentration ranging from 0.1 to 10 μM for 5 to 7 days.

The inhibitor caused both an increase in apoptosis and a decrease incell proliferation in a dose dependent manner (FIGS. 7B and 7C) asevidenced by an increase in AnnexinV stain and a decrease in Ki67 stain.Apoptosis as well as necrosis were induced specifically by treatmentwith INH-1R as opposed to a scrambled peptide sequence as evidence alsoby a combined Hoechst/PI/YO-PRO-1 stain (FIG. 8). Cell death can bemonitored also by FACS methods as visible in FIG. 9, were OVCAR-3 cellstreated for 24 hours with 10 μM of inhibitor showed a decrease in cellsize and increase in granularity, typical manifestations of cell death.

Specificity and efficacy of INH-1R were confirmed by up-regulation ofp53 target genes only in tumor cells bearing aggregation-prone mutationsas tested by QPCR (FIG. 8) or RNAseq methods.

In our in vivo studies, we attempted to mimic a post-surgical debulkingsituation in which patients with minimal residual tumor mass areadministered chemotherapy. NOD/SCID mice were injected subcutaneouslywith OVCAR-3 cells bearing the aggregation prone p53 R248Q mutation andtreated intraperitoneally with 15 mg/kg of either INH-1R as a singletherapeutic agent, a control scrambled peptide, or vehicle daily for 14days (FIG. 9). Mice treated with INH-1R showed diminished tumorproliferation, with a xenograft mass reduced by 75% in weight (FIGS. 9Band 9C). The residual tumor tissue showed a pronounced p21 and MDM2activation, indicative of p53 activation (FIG. 9D). The inhibitor wasalso tested in vivo on mice carrying pre-existing tumors with similareffect.

Pharmacokinetic profile of the intraperitoneally infused peptide showeda serum peak concentration of approx. 1.2 μM 1 hour after injection. Thepeptide concentration decreased to approximately 0.3 μM 2 hours postinfusion, and remained stable for up to 12 hours (FIG. 10). Given therelative stability of the peptide in serum, IV administration is anacceptable alternative route of administration.

From the foregoing description, one skilled in the art can easilyascertain the essential characteristics of this invention, and withoutdeparting from the spirit and scope thereof, can make changes andmodifications of the invention to adapt it to various usage andconditions and to utilize the present invention to its fullest extent.The preceding preferred specific embodiments are to be construed asmerely illustrative, and not limiting of the scope of the invention inany way whatsoever. The entire disclosure of all applications, patents,and publications cited herein, including U.S. provisional applicationSer. No. 61/821,157, filed May 8, 2013 and in the figures are herebyincorporated in their entirety by reference, particularly with regard tothe information for which they are cited.

REFERENCES

-   Naiki, H., Higuchi, K., Hosokawa, M., and Takeda, T. (1989).    Fluorometric determination of amyloid fibrils in vitro using the    fluorescent dye, thioflavine T. Anal. Biochem., 177, 244-249-   Hatakeyama S, Sugihara K, Shibata T K, Nakayama J, Akama T O, Tamura    N, Wong S M, Bobkov A A, Takano Y, Ohyama C, Fukuda M, Fukuda M N.    (2011). Targeted drug delivery to tumor vasculature by a    carbohydrate mimetic peptide. Proc Natl Acad Sci USA.    108(49):19587-92.-   Olson E S, Jiang T, Aguilera T A, Nguyen Q T, Ellies L G, Scadeng M,    Tsien R Y. (2010). Activatable cell penetrating peptides linked to    nanoparticles as dual probes for in vivo fluorescence and M R    imaging of proteases. Proc Natl Acad Sci USA. 107(9):4311-6.-   Jiang L, Liu C, Leibly D, Landau M, Zhao M, Hughes M P, Eisenberg    D S. (2013). Structure-based discovery of fiber-binding compounds    that reduce the cytotoxicity of amyloid beta. Elife 2:e00857.-   Goldschmidt L, Teng P K, Riek R, Eisenberg D. (2010). Identifying    the amylome, proteins capable of forming amyloid-like fibrils. Proc    Natl Acad Sci USA 107(8):3487-3492.-   Sawaya M R, Sambashivan S, Nelson R, Ivanova M I, Sievers S A,    Apostol M I, Thompson M J, Balbirnie M, Wiltzius J J, McFarlane H T,    Madsen A Ø, Riekel C, Eisenberg D. (2007). Atomic structures of    amyloid cross-beta spines reveal varied steric zippers. Nature    447(7143):453-457.-   Nelson R, Sawaya M R, Balbirnie M, Madsen A Ø, Riekel C, Grothe R,    Eisenberg D. (2005). Structure of the cross-beta spine of    amyloid-like fibrils. Nature 435(7043):773-778.-   Sievers S A, Karanicolas J, Chang H W, Zhao A, Jiang L, Zirafi O,    Stevens J T, Munch J, Baker D, Eisenberg D. (2011). Structure-based    design of non-natural amino-acid inhibitors of amyloid fibril    formation. Nature 475(7354):96-100.-   Ishimaru D1, Andrade L R, Teixeira L S, Quesado P A, Maiolino L M,    Lopez P M, Cordeiro Y, Costa L T, Heckl W M, Weissmüller G, Foguel    D, Silva J L (2003). Fibrillar aggregates of the tumor suppressor    p53 core domain. Biochemistry 42(30):9022-7.-   Lasagna-Reeves C A, Clos A L, Castillo-Carranza D, Sengupta U,    Guerrero-Muñoz M, Kelly B, Wagner R, Kayed R. (2013). Dual role of    p53 amyloid formation in cancer; loss of function and gain of    toxicity. Biochem Biophys Res Commun. 430(3):963-8.-   Silva J L, Vieira T C, Gomes M P, Bom A P, Lima L M, Freitas M S,    Ishimaru D, Cordeiro Y, Foguel D. (2010). Ligand binding and    hydration in protein misfolding: insights from studies of prion and    p53 tumor suppressor proteins. Acc Chem Res. 43(2):271-9.-   Ishimaru D, Ano Bom A P, Lima L M, Quesado P A, Oyama M F, de Moura    Gallo C V, Cordeiro Y, Silva J L. (2009). Cognate DNA stabilizes the    tumor suppressor p53 and prevents misfolding and aggregation.    Biochemistry 48(26):6126-35.-   Galea C, Bowman P, Kriwacki R W. (2005). Disruption of an    intermonomer salt bridge in the p53 tetramerization domain results    in an increased propensity to form amyloid fibrils. Protein Sci.    14(12):2993-3003.-   Rigacci S, Bucciantini M, Relini A, Pesce A, Gliozzi A, Berti A,    Stefani M. (2008). The (1-63) region of the p53 transactivation    domain aggregates in vitro into cytotoxic amyloid assemblies.    Biophys J. 94(9):3635-46.-   Levy C B, Stumbo A C, Ano Bom A P D, Portari E A, Carneiro Y, Silva    J L, De Moura-Gallo C V (2011). Co-localization of mutant p53 and    amyloid-like protein aggregates in breast tumors. The International    Journal of Biochemistry & Cell Biology 43:60-64.-   Eisenberg D and Jucker M (2012). The amyloid state of proteins in    human diseases. Cell 148(6):1188-203.-   Soussi, T., Ishioka, C., Claustres, M., and Beroud, C. (2006).    Locus-specific mutation databases: Pitfalls and good practice based    on the p53 experience. Nat. Rev. Cancer 6:83-90.-   Wilcken R, Wang G, Boeckler F M, Fersht A R. (2012). Kinetic    mechanism of p53 oncogenic mutant aggregation and its inhibition.    Proc Natl Acad Sci USA. 109(34):13584-9.-   Bullock and Fersht. (2001). Rescuing the function of mutant p53.    Nature Reviews Cancer 1, 68-76.-   Kayed, R., Head, E., Sarsoza, F., Saing, T., Cotman, C. W., Necula,    M., Margol, L., Wu, J., Breydo, L., Thompson, J. L., et al. (2007).    Fibril specific, conformation dependent antibodies recognize a    generic epitope common to amyloid fibrils and fibrillar oligomers    that is absent in prefibrillar oligomers. Molecular    Neurodegeneration 2:18-   Gannon, J V, et al, 1990, Activating mutations in p53 produce a    common conformational effect. A monoclonal antibody specific for the    mutant form, EMBO J., 9: 1595-602-   Xu J, Reumers J, Couceiro J R, De Smet F, Gallardo R, Rudyak S,    Cornelis A, Rozenski J, Zwolinska A, Marine J C, Lambrechts D, Suh Y    A, Rousseau F, Schymkowitz J. (2011). Gain of function of mutant p53    by coaggregation with multiple tumor suppressors. Nat Chem Biol    5:285-95.

We claim:
 1. A method for treating a subject having a cancer associatedwith p53 having an aberrant conformation, comprising administering tothe subject an effective amount of a pharmaceutical compositioncomprising a peptide represented by the sequence [L,Y,E,W] T [R,K], I T[L,Y] E (SEQ ID NO: 1), or an active variant thereof.
 2. The method ofclaim 1, wherein the peptide is represented by the sequence [L,Y,E,W] T[R,K], I T [L,Y] E (SEQ ID NO: 1), or an active variant thereof.
 3. Themethod of claim 1, wherein the peptide is represented by the sequence[L,Y,E,W] TRIT [L,Y] E (SEQ ID NO: 3), or an active variant thereof. 4.The method of claim 1, wherein the peptide consists of the sequence[L,Y,E,W] T [R,K], I T [L,Y] E (SEQ ID NO: 1).
 5. The method of claim 1,wherein the peptide consists of the sequence [L,Y,E,W] TRIT [L,Y] E (SEQID NO: 3).
 6. The method of claim 1, wherein the peptide consistscomprises one of the following sequences: (SEQ ID NO: 4) LTRITLE(SEQ ID NO: 5) YTRITLE (SEQ ID NO: 6) ETRITLE (SEQ ID NO: 7) LTRIYLE(SEQ ID NO: 8) YTRIYLE (SEQ ID NO: 9) WTRITLE (SEQ ID NO: 10) WTRIYLE(SEQ ID NO: 11) ETRIYLE (SEQ ID NO: 12) LTKITLE (SEQ ID NO: 13) YTKITLE(SEQ ID NO: 14) WTKITLE (SEQ ID NO: 15) ETKITLE (SEQ ID NO: 16) LTKIYLE(SEQ ID NO: 17) YTKIYLE, or (SEQ ID NO: 18) ETKIYLE


7. The method of claim 1, wherein the peptide is fused, optionally via alinker sequence, to a cell penetrating peptide (CPP).
 8. The method ofclaim 1, wherein the peptide is represented by the consensus sequence(R₁₋₁₆) P I [L,Y,E,W] T [R,K], I T [L,Y] E (SEQ ID NO: 19), or an activevariant thereof.
 9. The method of claim 1, wherein the peptide iscombined with a pharmaceutically acceptable carrier.
 10. A method fortreating a subject who has a mutant gene encoding p53 which imparts asusceptibility to develop cancers, comprising administering to thesubject a plurality of doses comprising in total an effective amount ofthe pharmaceutical composition of a pharmaceutical compositioncomprising a peptide represented by the sequence [L,Y,E,W] T [R,K], I T[L,Y] E (SEQ ID NO: 1), or an active variant thereof.
 11. A method fortreating a subject having a cancer associated with p53 having anaberrant conformation, comprising administering to the subject aneffective amount of a pharmaceutical composition comprising a peptiderepresented by the sequence (R₂₋₁₆) P I (L/Y/E/W) T (R/K) I T L E (SEQID NO: 19), provided the sequence does not comprise YTRITLE (SEQ ID NO:5).
 12. The method of claim 11, wherein the pharmaceutical compositioncomprises a pharmaceutically acceptable carrier.
 13. The method of claim11, wherein the peptide comprises the amino acid sequence LTRITLE (SEQID NO: 4).
 14. The method of claim 13, wherein the pharmaceuticalcomposition comprises a pharmaceutically acceptable carrier.
 15. Themethod of claim 11, wherein the peptide is coupled to 4 to 16 arginineresidues.
 16. The method of claim 15, wherein the peptide is coupled tothe arginine residues by a peptide linker comprising 1-7 amino acids.17. The method of claim 16, wherein the peptide forms a polycationicstructure.
 18. The method of claim 16, wherein the peptide forms anamphipathic structure.
 19. The method of claim 16, wherein the peptideis less than 30 amino acids in length.
 20. The method of claim 14,wherein the pharmaceutically acceptable carrier includes a peptidestabilizing excipient.
 21. The method of claim 20, wherein the peptidestabilizing excipient is a preservative that inhibits the growth ofmicroorganisms.
 22. The method of claim 11, wherein the peptidecomprises the sequence RRRRRRRRRRPILTRITLE (SEQ ID NO: 22).
 23. Themethod of claim 11, wherein the peptide comprises the sequence (R₂₋₁₆) PI L T R I T L E (SEQ ID NO: 19).
 24. The method of claim 1 furthercomprising inhibiting proliferation of cancer cells or shrinking a tumorin the subject.
 25. The method of claim 1 wherein the cancer is selectedfrom ovarian cancer, breast cancer, colon carcinomas and basal cellcarcinomas.
 26. The method of claim 10 further comprising preventing thedevelopment of tumors in the subject.
 27. A method of treating a subjecthaving a tumor with aberrant p53 conformation, the method comprisingadministering to the subject an effective amount of a pharmaceuticalcomposition comprising a peptide represented by the sequence [L,Y,E,W] T[R,K], I T [L,Y] E (SEQ ID NO: 1), or an active variant thereof.
 28. Themethod of claim 27 wherein the aberrant p53 conformation is aggregatedp53 or misfolded p53.
 29. The method of claim 28 wherein the compositionlowers the amount of p53 aggregates, or restores the folding of amisfolded p53.
 30. The method of claim 27 wherein the compositionre-activates a biological or biochemical activity of p53 disrupted bythe aberrant p53 conformation.